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ABSTRACT

Post-implant Dosimetry Analysis of Brachytherapy Patients Using Pre and Post
implant MRI
by
Deana Tuttle
Dr. Phillip Patton, Examination Committee Chair
Associate Professor o f Health Physics
University o f Nevada Las Vegas

Post-implant dosimetry analysis is a critical step in brachytherapy for identifying
the quality o f the implant based on seed localization in relation to the volume o f the
prostate. However, the accuracy o f post-implant dosimetry analysis is dependent on
accurate delineation o f the prostate from surrounding tissue in post-implant CT images.
Research has shown that adequately delineate the prostate from surrounding tissue in CT
images is difficult, resulting in significant variation between the dose received by the
prostate and the dose prescribed by the physician. This research compared prostate
volumes delineated from pre-implant US, post-implant CT, and pre and post-implant MR
images in order to develop a more reliable methodology to delineate the prostate. The
results illustrated the superiority o f MR imaging over CT imaging in delineation o f the
prostate thereby producing more individual and mean dosimetry values, D90 and V I00,
above their respective cut points o f 140 Gy and 85%.
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CHAPTER 1

INTRODUCTION
1.1 Purpose
Permanent seed implant brachytherapy has been proven to be a successful
treatment for patients with early stages o f prostate cancer with approximately 40,000
procedures being performed in 2000 (Potters et al. 2001). The increase in permanent seed
brachytherapy by clinical physicians has propelled research into developing better
methods o f detennining dose to the prostate by accurately delineating the prostate from
surrounding tissue using computed tomography (CT) and magnetic resonance (MR)
imaging.
Post-implant dosimetry analysis for permanent seed implant brachytherapy
patients is a crucial step in identifying the difference in the dose prescribed by the
physician in pre-planning to the actual dose delivered to the prostate and surrounding
tissue during surgery. In addition, it provides the physician a means o f evaluating the
seed distribution in relation to prostate volumes for future brachytherapy procedures.
Though research agrees that post implant dosimetry analysis is critical for evaluating the
quality o f the implant, currently there appears to be a lack o f standard procedures or
guidelines in post-implant dosimetry for practicing physicians (Nag et al. 2000).
Post-implant dosimetry analysis identifies the extent patients are being under or
overdosed. Therefore, the purpose o f this research is to compare the actual total dose the

1
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prostate received to the dose prescribed by the physician in Iodine-125 brachytherapy
patients based upon prostate volume differences by (I) determining differences in
prostate volumes calculated from pre-implant transrectal ultrasound (TRUS) images and
pre-implant magnetic resonance (MR) images, (2) determining differences in prostate
volumes calculated from post-implant computed tomography (CT) images and post
implant MR images, (3) determining differences in prostate volumes by fusing pre
implant ultrasound images with post-implant CT and MR images, (4) determining the
differences in the D90 value, the percent o f dose delivered to 90% o f the prostate volume,
the VIGO value, the percent o f the prostate volume receiving 100% o f the dose, and the
dose prescribed by the physician in the pre-planning stage to the total dose calculated in
the post-implant stage based upon prostate volumes differences, and (5) determine
systematic differences in MR and CT modalities by eliminating the problem o f
delineation o f the prostate from surrounding tissue by imaging phantoms o f known
volumes.

1.2

Anatomical Characteristics o f the Prostate and Surrounding Tissue

The prostate is a chestnut-sized organ located between the bladder and urogenital
diaphragm, just in front o f the rectum. It weighs approximately 8 grams and has the
dimensions o f 4 cm at the base, 2 cm anterior-posterior, and 3 cm vertically. It is situated
in the pelvis cavity just below the internal urethra orifice and the symphysis pubis and
above the superior fascia o f the urogenital diagram. The prostate surrounds the urethra
with the ejaculatory ducts passing through the posterior section o f the prostate from the
seminal vesicles and connecting with the urethra (Gray et al. 1918).
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The prostate is characterized by the base, apex, and four surfaces, the posterior
surface, the anterior surface, and two lateral surfaces. The base o f the prostate is located
inferior to the wall o f the bladder where the urethra enters the prostate’s anterior region.
The apex o f the prostate is located at the superior fascia o f the urogenital diagram as
shown in Fig. 1.

Vas Deferens
'\

(v3sa deferens)

Seminal
Vesicle
(cutaway view)

Seminal Vesicle
(surface view)

Base of
prostate
i

restate

P rostatic urethra

Figure 1. Illustration o f the prostate showing the seminal vesicles, prostatic urethra, apex,
and base o f the prostate (Bostwick et al. 1994).

The posterior surface is about 4 cm from the anus and is separated from the
rectum by its sheath and connective tissue. The anterior surface o f the prostate is located
about 2 cm behind the pubic symphysis and is where the urethra emerges from the
prostate in front and above the apex. The lateral surfaces o f the prostate are surrounded
by the anterior part o f the Levator ani muscles and are separated from the muscles by an
array o f veins (Gray et al. 1918).
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The majority o f the prostate’s mass is composed o f glandular tissue which is
defined by zonal anatomy (Gray et al. 1918). The transition zone (TZ) is located between
the anterior fibromuscular stroma and the peripheral zone (McLaughlin et al. 2005).
About 20% o f prostate cancer will originate in the transition zone (Rangabashyam et al.
2001). The peripheral zone (PZ) is located between the rectum wall and the transition
zone (McLaughlin, et al. 2005, Watson et al. 1997) and encompasses about 70% o f the
prostate gland. This zone is where 70% o f prostate cancer will originate (Rangabashyam
et al. 2001, Watson et al. 1997). The central zone (CZ) represents the tissue at the base of
the prostate and encompasses the ejaculatory ducts located within the prostate.
Approximately 10% o f prostate cancer will originate here (Rangabashyam et al. 2001).

1.3

Permanent Seed Prostate Brachytherapy

Permanent seed brachytherapy is the placement o f radioactive seeds in the
prostate using interstitial brachytherapy techniques which include 3D anatomically based
dosimetry planning and guidance from real-time diagnostic imaging. This method of
treating prostate cancer is currently the most prescribed plan in the United States (Peschel
et al. 2003). It is widely chosen because it is low cost, has a short recovery time, produces
excellent long-term results from biochemical failure, and has low morbidity (Peschel et
al. 2003). Application o f brachytherapy for treatment o f prostate cancer can be prescribed
two ways, as a monotherap (a treatment plan with just permanent seed brachytherapy) or
as a combination therapy (a treatment plan with permanent seed brachytherapy in
addition to external beam radiation) (Peschel et al. 2003). In a study by Potters et al.
(2004), prostate cancer patients were treated with radical prostatectomy, external beam

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

radiation, or permanent seed brachytherapy. Results indicate similar rates in freedom
from biochemical failure for all three treatment plans. The overall survival was 97% for
radical prostatectomy, with 96% for external beam, and 93% for brachytherapy.
Compared to external beam radiation and radical prostatectomy, brachytherapy has fewer
cases o f urinary or rectal complications and sexual dysfunction (Yu et al. 1999).
With the increase o f brachytherapy treatment as an option for many prostate
cancer patients due to the early diagnoses obtained from monitoring PSA levels (Yu et al.
1999), research has begun to focus on identifying the variables that affect the outcome of
the procedure. The goal o f prostate brachytherapy is to deliver the prescribed dose to the
prostate while minimizing the dose received by the urinary and rectal areas using a 3D
anatomically based treatment plan, an interoperative treatment plan, and an analysis of
post-implant dosimetry (Yu et al. 1999). However, research conducted by the clinical
research committees o f the American Brachytherapy Society (ABS) and the Prostate
Brachytherapy Quality Assurance Group (PBQAG) conclude that there is a wide
variation in indicators, techniques, treatment regiments, and dosimetry for treating
prostate cancer with brachytherapy. Two major areas o f concern the committees
addressed were pre-implant treatment planning and post-implant dosimetry analysis, both
o f which are dependent upon being able to acquire accurate prostate volumes from 2D
images.

1.4 Dose Margin
One factor that has been identified that contributes directly to post-implant
dosimetry is the dose margin used for the implant (Yu et al. 1999, Waterman et al. 1998).
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Because o f uncertainties in seed distribution, the percent o f the prostate volume receiving
the prescribed dose is almost always less than what was plarmed. To ensure adequate
dose coverage, a plarming volume larger than the prostate volume is used to ensure dose
coverage beyond the prostate capsule. Alternatively, the physician can increase the
strength o f the seeds or increase the number o f seeds to be implanted until the prescribed
isodose line extends several millimeters beyond the prostate (Yu et al. 1999).
The 1998 study by Waterman et al. illustrates how margin determination during
pre-implant planning can directly affect dose coverage. In a comparison between a dose
margin which closely contoured the pre-implant prostate volume to a standard dose
margin that extended several millimeters beyond the periphery o f the prostate, the pre
implant plan with little or no margin had less dose coverage than the pre-plan with a
standard dose margin due to post-implant edema. As the prostate swelled from the edema
after the implant, it was still covered by the isodose lines from the dose margin being
extended past the peripheral o f the prostate capsule during the pre-planning stage
(Waterman et al. 1998).

1.5 Edema
Edema also influences the dose coverage due to the increase in prostate volumes
from implant trauma. Compared to pre-implant volumes, edema can increase prostate
volume as much as 96% with an average increase in prostate volumes o f 52% (Waterman
et al. 1998). This increase in prostate volume results in an increase in the separation
between the implanted seeds thus lowering the percentage o f the prostate volume that is
receiving 100% o f the prescribed dose (Yu et al. 1999, Waterman et al. 1998, Taussky et
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al. 2005). However, a CT scan done after the edema has completely resolved will result
in an overestimation o f the dose delivered to the prostate because the dose being
delivered during the time the edema is resolving will not be accurately accounted for by
the post-implant dosimetry analysis is calculated (Yu et al. 1999). Since Iodine-125
delivers 90% o f its total dose in the first 197 days after the implant, scheduling the time
for post-implant CT scans is not only dependent upon the edema, it is also dependent
upon the type of seed used in the implant (Yu et al. 1999, Waterman, et al. 1998).
Therefore, a CT scan performed immediately after the implant will underestimate the
dose delivered to the prostate while CT scans performed after all the edema has resolved
will overestimate the dose delivered to the prostate. Studies suggest the optimal time for
1-125 post-implant dosimetry analysis is 30 days after treatment (Yu et al. 1999, Helmick
et al. 2002, Taussky et al. 2005).

1.6

Source Type and Source Distribution

The two radionuclides used for low-dose rate brachytherapy are 1-125 and Pd103. Both are similar in dose distribution, dimensions, and photon energy. Iodine-125
seeds are encapsulated in titanium with outer dimensions o f 4.5 mm x 0.8 mm for the
most commonly used type o f seed. Model 6711. Model 6711 contains 1-125 in the form
o f silver iodide deposited on the surface o f a silver rod, which serves as a radiographic
marker. The average overall energy for all 1-125 emissions is 27.4 keV with a half-life o f
59.4 days. Since clinical studies do not show any difference in patient outcomes or
complications with either 1-125 or Pd-103, the ABS does not make a radionuclide
preference for prostate brachytherapy.
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There are three different types o f seed distribution that can be applied in
brachytherapy; uniform loading, modified peripheral loading, and peripheral loading.
The uniform loading spaces the seeds 1 cm apart throughout the prostate resulting a
higher dose in the center o f the prostate. The modified peripheral loading is similar to the
uniform loading distribution except some seeds are deleted in the center o f the prostate to
reduce the central dose. Peripheral loading places the seeds along the peripheral o f the
prostate sparing the urethra from receiving unnecessary dose. Also, with 70% o f prostate
cancer being located in the peripheral zone, peripheral loading for seed distribution is the
most commonly applied method o f source distribution. This method o f seed distribution
can maximize the prescribed dose to the periphery o f the prostate while minimize the
dose to the urethra (Yu et al. 1999).

1.7

Freedom from Biochemical Failure

One o f the most important applications o f post-implant dosimetry is determining
the time in which the patient is cancer free or free from biochemical failure after
completion o f the treatment. The success o f the treatment is measured by the patient’s
prostate specific antigen (PSA) scores, Gleason scores, and/or biopsy results. Current
research can support evidence to directly correlate the freedom from biochemical failure
in permanent seed implant to two post-implant parameters, D90, the dose delivered to
90% o f the prostate volume, and V I00, the amount o f prostate volume receiving 100% of
the prescribed dose (Gong et al. 2002). O f these, the best dosimetry parameter to describe
the amount o f dose delivered to the prostate is the D90 parameter (Nag et al. 1999). The
D90 parameter is more commonly used instead o f the DlOO parameter because there arc
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small errors in contouring the prostate in addition to small areas within the prostate that
have been under dosed, making the DlOO parameter an incorrect representation o f the
actual dose being delivered to the prostate volume.

In addition, D90 is the only

dosimetric parameter that has been directly correlated to PSA response (Stock et al.
2002 ).
Research has identified a D90 cut point value o f 140 Gy (Polo et al. 2004, Stock
et al. 2000, Wallner et al. 2003, McNeely et al. 2004, Merrick et al. 1999, Kollmeier et al.
2003) and a V I00 eut point o f 85% (Polo et al. 2004, Wallner et al. 2003) for 1-125
sources using CT based dosimetry. The relationship between freedom from biochemical
failure and D90 value is illustrated in a study by Stock et al. (1998) which showed 68%
o f patients who received a D90 less than 140 Gy were free from biochemical failure
compared to 92% o f patients who received D90 greater than 140 Gy. A similar study by
Wallner et al. (2003) illustrated the relationship between V I00 and biochemical failure
where 97% o f the patients that had a V I00 greater than 90% were free from biochemical
failure compared to only 87% o f the patients who had V I00 less than 90%.
In the 2004 study by Polo et al. that compared CT and CT/MR dosimetric
parameters, D90 and V I00, showed superior results from CT/MR imaging due to volume
definition from the MR images instead o f CT images. D90 values were only 116 Gy for
the CT images yet the CT/MR fused images resulted in D90 values o f 158 Gy. The V I00
also showed the same results with 82% coverage measured from the CT images
compared to 88% coverage measured from the CT/MR fused images (Polo et al. 2004).
Research has determined the accuracy o f post-implant dosimetry analysis is
dependent upon successful delineation o f the prostate from surrounding tissue, and that
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current imaging practices are unable to adequately produce true prostate volumes. As a
result, MR imaging o f the prostate or applying multiple imaging modalities and fusing
the images is being proposed in this research as a method o f enhancing current post
implant dosimetry analysis by more accurately measuring the prostate volume.

1.8 Brachytherapy Imaging Modalities
1.8.1 Pre-implant Ultrasound (US) Volume Study and Computed Tomography (CT)
Imaging
Transrectal ultrasound (TRUS) imaging is used by praeticing clinical oncologists
for pre-planning, implantation, and post-implant dosimetry analysis. During the pre
planning stage, ultrasound images are obtained during a volume study two to three weeks
before the implant using TRUS images. The volume study provides pre-implant treatment
planning information including the number and strength o f the seeds to be implanted, grid
coordinates for needle placement during surgery, and the dose distribution. Peripheral
dose distribution is emphasized to reduce central hot spots in the prostate thus reducing
urinary complications (Nag et al. 1999). The pre-implant US images obtained during the
volume study are also used by physicians during the implant stage for seed distribution in
relation to the border o f the prostate. For post-implant dosimetry analysis, the US images
are fused with CT images, which provide seed localization information. Using US images
solely for post-implant dosimetry analysis would have advantages o f being more
accurate, less expensive, and faster, than CT imaging. However, US can not be used after
implantation because o f the frequency disruption the titanium seeds produce which
manifests as a shadowing of the seeds farthest from the probe (Solhjem et al 2004).

10
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The optimum post-implant imaging modality would be able to determine seed
location and to delineate the prostate from the surrounding tissue. Fusion o f the pre
implant ultrasound images to post-implant CT images are commonly used for post
implant dosimetry analysis with the prostate volume information being supplied by the
US and seed localization information being supplied by the CT. The posterior border o f
the prostate and urethra can be used to register the two images with the calculated isodose
curves being superimposed on the resulting fused image (Nag et al. 1999).
The issue with applying CT imaging for fusion with US images for post-implant
dosimetry analysis is illustrated in previous studies that show prostate volumes delineated
from CT images are on the average 30% to 50% larger than prostate volumes delineated
from MR or US images making the difference in prostate volumes from the CT images a
major concern in regards to the accuracy o f post-implant dosimetry analysis (Helmick et
al. 2002, Steggerda et al. 2004, Prete et al. 1998, Solhjem et al. 2004). Even with an
experienced oncologist, research has concluded that the contouring o f prostate volumes in
CT images is difficult and the uncertainty in adequately defining the volume can
significantly affect the post-implant dosimetry analysis (Crook et al. 2002, Anderson et
al. 1999).
The importance o f CT based post-implant dosimetry lay not only in being able to
precisely delineate prostate volumes, but being able to do it consistently among different
observers. Research has also shown that there has even been a large discrepancy in
outlining the CT prostate volumes among different physicians. From the study by
Narayana et al. (1995), the volumes contoured on pre-implant CT images were 13%,
35%, and 92% larger than volumes contoured on pre-implant US images by three

11
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different physicians. On average, the prostate volumes defined in the pre-implant CT
images were 47% larger and 0.6 cm longer than the volumes defined in the US images.
The difference in prostate volumes delineated by the three observers illustrates the
difficulty in distinguishing the prostate from surrounding tissue in CT images.
1.8.2 Computed Tomography (CT) and Magnetic Resonance (MR) Imaging
Several studies have reported large discrepancies in prostate volumes delineated
from CT images compared to volumes delineated from US or MR images (Polo et al.
2004). In one study by Rasch et al. (1999) prostate volumes contoured from CT images
were 30% larger than volumes contoured from MR images. Another study illustrated the
ability o f MR imaging to accurately represent the actual volume o f the prostate (Amdur et
al. 1999) where prostate volumes were measured using US and MR imaging prior to
radical prostatectomy. The prostate volumes delineated from the US images were 8%
larger and volumes delineated from the MR images were only 6% larger than the actual
surgical specimen.
The specific problem reported with using CT imaging is the difficulty in
delineating the apex, base, and seminal vesicles from surrounding tissue and
distinguishing the prostate from the prostatic muscles and the periprostatic venous plexus
(Nag et al. 1999, Dubois et al. 1998, Potters et al. 2001, Crook et al. 2004, Rasch et al.
1999, Amdur et al. 1999, McLaughlin et al. 2002, Polo et al. 2004, Helmick et al. 2002,
Badiozammani et al. 1999, Algan et al. 1995). Other crucial problems identified in using
CT imaging include distinguishing the posterior section o f the prostate from the anterior
wall o f the rectum, difficulty in distinguishing between the posterior-inferior apical
portion o f the prostate from the anterior portion o f the levator ani muscles, the inclusion

12
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o f neurovascular bundles as part o f the prostate, and distinguishing the superior edge o f
the prostate from the bladder (Al-Qaisieh et al. 2002, Crook et al. 2004, Potters et al.
2001, Roach et al. 1996, Polo et al. 2004, McLaughlin et al. 2002). The greatest area o f
uncertainty in defining boundaries in CT images is located at the most inferior or apical
portion o f the prostate. This region is o f major concern to oncologists since 75% to 85%
o f prostate cancers involve the apical region o f the prostate requiring optimum dose
coverage to this area (Roach et al. 1996).
Inter-observer variation is also a significant factor when comparing the
delineation o f prostate volumes from CT and MR images. Inter-observer differences on
CT prostate volumes were significantly larger with volume differences ranging from 35
cm^ to 70 cm^, a 100% difference in half o f the patients in a study by Amdur et al.
(1999). In comparing prostate volume differences using CT and MR fused images, the
study revealed prostate volumes contoured in the CT images were 32% larger than the
volumes contoured in the MR images.
A solution to the overestimation o f prostate volumes delineated in CT images is
the application o f MR imaging. MR imaging offers better soft tissue delineation and can
be correlated with US evaluations and pathological results. In addition, MR imaging can
produce better inter-observer reproducibility and fusion o f CT and MR imaging is being
researched as a means o f assessing implant quality (Polo et al. 2004). MR imaging is
favored over CT imaging because o f its reproducible and consistent delineation o f
prostate volumes (Crook et al. 2003). Dubois et al. (1998) showed a difference o f 18.2%
between the mean inter-observer variations o f prostate volumes contoured on CT images
among two different observers. However, the mean inter-observer variation in prostate

13
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volumes contoured on the MR images had an 8.3% difference and more consistency.
Prostate volumes contoured from MR images have also shown to correlate closely with
volumes measured from pathological examinations (Dubois et al. 1998) and are
considered to be the gold-standard for prostate volume definition (Parker et al. 2003,
Amdur et al. 1999).

1.9

Post-implant Brachytherapy Dosimetry Analysis

Post-implant dosimetry is used to identify any variation in the treatment plan in
order for the physician to evaluate the quality o f the implant by calculating the actual
dose delivered to the prostate, urethra, rectum, and surrounding tissue (Yu et al. 1999,
Nag et al. 1999). The post-implant dosimetry parameter used to determine the quality of
the implant and to predict freedom from biochemical failure is D90. Studies conducted at
Memorial Sloan-Kettering have shown the D90 dosimetry value is very sensitive to small
differences and perturbations in the location o f the seeds and target delineation (Nag et al.
1999). A study by Polo et al. (2004) illustrated that post-implant dosimetry is so sensitive
to volume definition that if prostate boundaries are enlarged on CT images by 4 mm from
the actual volume, D90 values will decrease from 171 Gy to 98 Gy and V I00 will
decrease from 95% to 72%, well below their respective cut points. But when permanent
seed prostate brachytherapy is pre-planned with the sources having D90 and V I00
dosimetry parameters greater than their cut point values, patients have a 10-year local
recurrences-free survival rate which is twice that o f patients having dosimetry parameters
below the cut point values (Nath et al. 1998). With post-implant dosimetry values
dependent upon prostate volumes delineated from CT imaging with studies concluding
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that volumes contoured from CT images are significantly overestimated, research is
supporting the implementation o f MR imaging for prostate radiation treatment planning
(Parker et al. 2003).
The goal o f this research is to calculate the difference in prostate volumes
delineated from pre-implant US, post-implant CT, and pre and post-implant MR images
to identify the impact volume definition has on post-implant dosimetry values, D90 and
V I00.

15
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CHAPTER 2

VOLUME ESTIMATION OF 25 ML, 50 ML, AND 100 ML FLASKS USING
COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING
2.1 Introduction
The accuracy o f post-implant dosimetry analysis in the evaluation o f prostate
cancer patients depends upon being able to delineate the prostate in 2D images. The
ability to obtain accurate prostate volumes from either CT or MR images is dependent
upon various factors. Two such variables are differentiation o f prostate tissue from
surrounding tissue and the problem o f subjectivity. Due to poor definition o f soft tissue in
CT images, the inclusion o f surrounding tissue with the delineation o f the prostate in CT
images has resulted in an increased volume estimate that differs significantly from the
actual volume o f the prostate (Al-Qaisieh et al. 2002). Previous research has shown
prostate volumes delineated from CT images are on the average 40% larger than prostate
volumes delineated from other imaging modalities (Steggerda et al. 2004) raising
questions in the accuracy o f post-implant dosimetry analysis (Helmick et al. 2002,
Steggerda et al. 2004, Prete et al. 1998, Solhjem et al. 2004). Subjectivity has also been a
concern in prostate brachytherapy post-implant dosimetry analysis where dosimetry
parameters, D90 and V I00 are calculated based on delineating prostate volumes from CT
images (Badiozamani et al. 1999). Dubois et al. (1998) showed that there are smaller
inter and intra observer differences with volumes contoured from MR images than
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volumes contoured from CT images concluding that MR imaging is more precise and
more accurate in delineating the prostate for evaluation o f permanent seed prostate
implantation. These results suggest that the subjectivity associated with delineating
prostate volumes on CT images makes the accuracy o f the dosimetric evaluation based on
CT imaging questionable.
The purpose o f this portion o f the research is to determine systematic differences
in MR and CT modalities by eliminating the problems o f subjectivity in prostate
contouring and delineation o f the prostate from surrounding tissue by imaging phantoms
o f known volumes.

2.2

Research Methodology

Three borosilicate volumetric flasks with defined volumes o f 25 ml, 50 ml, and
100 ml were used as phantoms. These particular flasks were selected for their ellipsoidal
shape which mimics the shape o f the prostate. The flasks were filled with distilled water
and submerged in water to simulate a prostate gland inside the pelvic region (Fig. 2). The
flasks were placed on top o f a clay pedestal to ensure the boundary between the glass
flask and glass jar didn’t interfere with delineation in the CT and MR images. Styrofoam
cones were bored out with the stem o f the flasks placed inside to ensure stability and to
prevent changes in the water level inside the flasks and jars.
The phantoms were imaged individually with a GE SIGNA LX EXCITE 1.5 T
MRI scanner with a GE Toropa coil and a Medrad endorectal coil interface. The
phantoms were scanned in the axial plane with a T2 FRFSE (Fast Recall, Fast Spin Echo
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sequence with an 18 cm field o f view and 24 slices o f 3.0 mm thickness. A 2D MRI slice
o f the 50 ml flask is shown in Fig. 3.

Figure 2. 25 ml, 50 ml, and 100 ml flasks filled with distilled water and placed inside
water phantoms.

The three flasks were also imaged with a Philips CT helical scanner in the axial
plane with 16 slices o f 3 mm thickness with a 3 mm gap. Figure 4 shows a 2D CT image
o f the 100 ml flask. The axial T2 MR and axial CT image sets were loaded onto the
Varian Variseed software in order to contour the flask volumes.

18
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Figure 3. A 2D 3 mm slice obtained from the MR image o f the 50 ml flask filled with
distilled water and placed inside a water phantom.
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Figure 4. A 2D slice extracted from the CT data set o f the 100 ml flask filled with
distilled water and placed inside a water phantom.

2.3 Results
The results of contouring the 25 ml, 50 ml, and 100 ml flasks from MR and CT
images are given in Table 1. The contoured volumes o f the three flasks from the CT
images showed significant differences from the actual volumes o f the flasks. The
20
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contoured volume o f the 25 ml flask was 18.0 em^, a percent error o f 27.9%. Similar
results were seen with the 50 ml and 100 ml flasks. The contoured volume o f the 50 ml
flask was 37.4 cm^, a pereent error o f 25.2% and the 100 ml flask’s contoured volume
was 77.0 em^, a pereent error o f 23.0%.

Table 1. Volumes o f the 25 ml, 50 ml, and 100 ml flasks contoured from the CT and MR
images along with the percent error from the original volumes in parenthesis.
Flask Volumes (ml)

CT Volume (ml)

MR Volume (ml)

25

18.0

(27.9)

23.3

(6.20

50

37.4

(25.2)

47.5

(5.0)

100

77.0

(23.0)

96.6

(3.4)

Compared to CT imaging, the volumes contoured from the MR images were
closer to actual volumes o f the three flasks. The contoured volume o f the 25 ml flask
from the MR images was 23.3 cm^ or 6.8% smaller than the actual volume. The
contoured volume o f the 50 ml flask was 47.5 em^, a 5.0% pereent error and the
eontoured volume o f the 100 ml flask was 96.6 cm^, a 3.4% percent error. These results
show that the volumes contoured from the CT images underestimated the actual volumes
o f the flasks from 23.0% to 27.9% but the volumes contoured from the MR images only
underestimated the actual volumes o f the flasks by 3.4% to 6.8%.
The data also indicate that smaller contoured volumes experience larger
differences from the actual volume in both CT and MR images. The difference o f the 25
ml volume contoured in the CT images was 27.9% compared to 25.2% for the 50 ml flask
and 23.0% for the 100 ml flask. Similar results were seen in the MR images with the 25
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ml flask having a percent error o f 6.8% compared to the 5.0% for the 50 ml flask and
3.4% for the 100 ml flask. Since the optimum prostate volume for brachytherapy is in the
25 ml to 50 ml range, the larger differences seen with the delineation o f smaller volumes
in the CT and MR images will greatly impact dosimetry analysis.
The volumes contoured from CT and MR images of the 25 ml, 50 ml, and 100 ml
flasks are plotted versus the actual volumes o f the flasks in Fig. 5. Figure 5 shows a linear
relationship with a correlation coefficient o f 0.999 for both imaging modalities.

Flask Volumes versus Contoured CT and M R Volumes
120 n

100

80
— C T Volumes (ml)
— M R Volumes (ml)

100

125

Flask Volumes
Figure 5. The contoured volumes from the CT and MR images are plotted against the
actual volumes o f the flasks illustrating a linear relationship between the flask volumes
and the CT and MR volumes.

Graphical analysis o f the flasks in Fig. 5 shows a correlation o f 0.79 to the
volumes contoured from the CT images (blue line) and 0.98 to the volumes contoured
from the MR images. From these results, volumes contoured from CT images will
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consistently be 21% smaller than the actual volume but volumes contoured from MR
images will only be 2% smaller.

2.4 Conclusion
The discrepancy in the contoured volumes o f the flasks from CT and MR images
was larger in the CT imaged volumes than from the MR imaged volumes. The contoured
volumes o f the flasks from the CT images were 23.0% to 27.9% smaller than the original
volumes o f the flasks. But the contoured volumes o f the flasks from the MR images were
only 3.4% to 6.8% smaller than the volumes o f the original flasks. These results agree
with results o f previous research showing that volumes contoured on MR images
correlate more closely to pathological specimen (Roach et al. 1996, Polo et al. 2004,
Frété et al. 1998, Dubois et al. 1998). Furthermore, these results illustrate why prostate
volumes contoured from MR images are considered to be the gold-standard in prostate
brachytherapy pre-implant dosimetry planning and in post-implant dosimetry analysis
(Amdur et al. 1999, Parker et al. 2003).
Graphical analysis o f the three flasks show a linear relationship between the
volumes o f the original flasks and the volumes contoured from the CT and MR images.
Graphing the volume o f the flask with the volumes contoured from the CT images
illustrates that the CT images underestimated the volume o f the flasks by 21%. However,
graphing the volume o f the three flasks with the volumes contoured from the MR images
shows that the MR images only underestimated the volumes by 2%.
Though there is a significant difference in the magnitude in which the CT images
underestimated the volumes o f the flasks compared to the MR images, there was one very
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distinct similarity between the two imaging modalities. The data illustrated that the
smaller volumes delineated in both CT and MR images had larger differences from the
actual volumes o f the flasks than the larger volumes. The significance o f these results
indicate that images o f prostate volumes ranging from 25 ml to 35 ml will exhibit larger
differences in volumes contoured from MR and CT images than prostate volumes o f 40
ml to 50 ml, making post-implant dosimetry analysis less accurate for smaller prostate
volumes. This result is supported in a study by McNeely et al. (2004) where 20% o f small
prostate volumes had D90 dosimetry values less than 140 Gy while medium prostate
volumes had 9% and larger prostate volumes had only 3% less than 140 Gy.
The prostates imaged in vivo show an increase in volumes in both CT and MR
images rather than a decrease as shown from imaging the flasks. The discrepancy in
volume differences between in vivo imaging o f prostates and imaging o f the flasks
illustrates the difficulty in delineating prostate tissue from the surrounding soft tissue in
the images. The results also show the CT images o f the flasks created well defined
glass/water boundaries, eliminating any ambiguity in defining the glass from the water.
Yet, there was still a significantly larger difference between the volumes contoured from
the CT images than the volumes contoured from the MR images. This indicates that CT
imaging will generate images that have a larger difference from the actual volume then
MR images. The research illustrates how volumes contoured in MR images represent a
more accurate definition o f the actual volumes in comparison to images contoured in CT
images with smaller volumes experiencing larger differences than larger volumes in both
imaging modalities.
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CHAPTER 3

COMPARISON OF ULTRASOUND, COMPUTED TOMOGRAPHY, AND
MAGNETIC RESONANCE IMAGING FOR POST-IMPLANT
DOSIMETRY ANALYSIS
3.1 Introduction
Post-implant dosimetry analysis for brachytherapy permanent seed implant is a
crucial step in identifying differences in the dose prescribed by the physician in pre
planning and the actual dose delivered to the prostate and surrounding tissue. This
analysis identifies the extent patients are under or overdosed based on delineation o f the
prostate volume using current imaging modalities and image fusion software. Though
research agrees that post implant dosimetry analysis is critical for evaluating the quality
o f the implant and is needed to improve future brachytherapy procedures, currently there
appears to be a lack o f standard procedures or guidelines in post-implant dosimetry for
practicing physicians (Nag et al. 2000).
Permanent seed implantation o f the prostate occurs in three stages, pre-implant,
implant, and post-implant. In the pre-implant stage, TRUS is used to determine the
clinical target volume (CTV). This is the standard volume used by the physician to define
the prostate geometry for pre-implant dosimetry which allows the physician to correctly
determine seed distribution. The ultrasound images are also used during the implant stage
for prostate delineation and correct seed localization and distribution. However, for the
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post-implant stage, post-implant CT images have to be fused with pre-implant US images
because physicians have difficulty in distinguishing the prostate from the surrounding
soft tissue in the CT images used for seed localization (McLaughlin et al. 2002, Rasch et
al. 1999, Potters et al. 2001, Yu et al. 1999, Roach et al. 1996). A CT image o f the
prostate and surrounding tissue shown in Fig. 6 illustrates the problems with contouring
the prostate from the surrounding tissue.

Figure 6. CT image o f post-implant Iodine-125 seed implant illustrating excellent seed
localization but poor delineation o f prostate from surrounding tissue.

To overcome the limitations o f CT imaging in defining prostate volumes, MR
imaging is proposed in post-implant stages o f brachytherapy. Post-implant comparison
between MR and CT imaging conducted by Dubois et al.(1998) shows MR images have
significantly better boundary definition o f prostate volumes and offers better apex
definition than CT.

26

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Though tissue differentiation in MR imaging is superior to CT imaging as seen in
Fig. 7, seed location and distribution is better defined in CT images. To resolve this issue,
fusion o f CT images for seed localization information and MR images for volume
information is currently being investigated (Graves et al. 2001).

Figure 7. MR image o f post-implant Iodine-125 permanent seed implant illustrating the
excellent delineation o f the prostate from surrounding tissue but the poor resolution o f the
seeds.

In this research, prostate volumes delineated from pre and post-implant MR images
were compared to prostate volumes delineated from pre-implant US and post-implant CT
to determine the differences in volume measurements among the different imaging
modalities. After the US, CT, and pre and post-implant MR images were acquired, the
prostate glands were contoured and the images were fused for comparison. In addition,
the dosimetry parameters, D90 and V I00 were compared between the imaging modalities
to identify how they are affected by the delineation o f the prostate volumes.
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3.2 Research Methodology
3.2.1 Participant Selection
Eight patients that elected to have permanent seed implant for treatment o f prostate
cancer participated in this research. Since this research is investigating delineation o f
prostate volumes with different imaging modalities, any outside variable that would
change the prostate volume, such as hormone therapy or external beam radiation,
excluded patients from being able to participate.
Before the study began, approval was granted by each patient according to the
Institutional Review Board (IRB). The research was approved by the IRB o f the
Northwest Hospital Medical Center in Tucson, Arizona on June 8, 2005.
3.2.2 Pre-implant Brachytherapy Transrectal Ultrasound Volume Study
In the pre-implant stage, the oncologist determined the patient’s prostate volume in
using TRUS. The TRUS uses a rectal probe in conjunction with a Foley Catheter to
introduce contrast into the urethra. The ultrasound was performed in 5 mm increments
starting at the base o f the prostate and continuing to the apex with the patient in a dorsal
lithotomie position.
The pre-implant US images were used for dose distribution calculations using the
Varian VariSeed™* Version 7.1 software and for seed distribution and seed placement
during the implant. Figure 8 illustrates a brachytherapy dosimetry plan with isodose lines
and seed distribution according to grid coordinates. The urethra and rectum walls are
located in order to avoid overdosing these organs during implantation.

' Varian Medical Systems, 3100 Hansen Way, M/S MGM, Palo Alto, CA 94304-1038
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Figure 8. Brachytherapy dosimetry pre-implant plan with isodose lines and seed
distribution (yellow dots) according to grid coordinates that match the grid on volume
study US images. The dosimetry pre-plan includes seed placement in peripheral loading
pattern for urethra dose sparing.

The planning target volume (PTV) was extended 5 mm beyond the prostate
capsule to ensure all cancer cells were dosed. The seeds were distributed according to the
peripheral seed distribution method. The activity o f the seeds and the number o f seeds to
be implanted were determined based on the prostate volume and surgery date with an
average dose prescribed o f 145 Gy.
3.2.3 Pre and Post-implant MR Scans
Before the implant surgery, the patients had an MR scan at a diagnostic imaging
center. The MR spectrometer used in this research for pre and post implant scans was a
GE SIGNA LX EXCITE 1.5 T spectrometer with a GE Toropa coil and a Medrad
endorectal coil interface. Each patient was scanned with an axial T2 FRFSE (Fast Recall,
Fast Spin Echo), and axial T1 FRFSE with fat saturation. Fat saturation gave us the
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ability to change the contrast o f fatty tissue in the pelvic area to better delineate tbe
prostate from the surrounding tissue. These MR imaging parameters were defined as the
optimum settings to provide the best images o f the prostate and surrounding tissue.
Parameters for the axial T2 FRFSE and the axial T1 FRFSE scans are given in Table 2.

Table 2. MR imaging parameters for pre and post-implant axial T2 FRFSE (Fast Recall,
Fast Spin Echo) and T1 FRFSE pulse sequences.
Axial T2 FRFSE

Axial T1 FRFSE

85 ms
4750 ms
18 cm
3.0 mm
24

14 ms
375 ms
18 cm
3.0 mm
24

Time o f Echo (TE)
Time o f Repetition (TR)
Field o f View (FOV)
Slice Thickness
Number of Slices

Time o f Echo (TE) is the time between the initial pulse and the peak o f the echo.
Time o f Repetition (TR) is the time between excitation pulses. Both TE and TR are
imaging parameters selected based upon T1 or T2 weighted imaging.
3.2.4 Implant Procedure
Approximately two to three weeks after the volume study, the patients were
admitted to Northwest Medical Center for outpatient brachytherapy permanent seed
implant. After being brought into the operating room and placed under general
anesthesia, the patients were positioned in a dorsal lithotomie position. During the
implant, ultrasound images obtained during the volume study, in addition to fluoroscopy
imaging, were used for accurate seed placement within the prostate.
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The

patients

were

implanted

with

pre-loaded

Iodine-125

seeds.

After

implantation, the bladder was drained by the patient’s urologist. The patient was taken to
post-op, brought out o f the anesthesia, and released.
3.2.5 Post-implant Procedure
Approximately 30 days after surgery, the patients returned for a post-operative
exam. At this time each patient had a CT and MR scan. The CT scanner is a helical multi
slice, 16 channel scanner. The images were acquired in 3 mm increments. The MR scan
had the same parameters as the pre-implant MR scan.
The Pre-implant US, Post-implant CT, and Planning Target Volume (PTV) data
were the only information used for patient pre and post treatment planning and analysis.
All other images and data were used solely for research purposes.
3.2.6 Prostate Volume Delineation, Seed Localization, and Dosimetry Parameters
The prostate volumes were determined by contouring the CT images and the pre
and post-implant MR images on the Varian Variseed software. The pre-implant
ultrasound volumes and post-implant CT images were contoured by the oncologist
(Observer 1). The radiologist (Observer 2) contoured the pre-implant and post-implant
MR images. This researcher (Observer 3) contoured the pre-implant MR, post-implant
MR, and post-implant CT images. All prostate volumes were contoured without a
margin. The dosimetry values, D90 and V I00, were generated from the pre-implant US
images, post-implant CT images, and post-implant MR images.
Seed localization was determined for all 8 patients on the post-implant CT images
that were contoured by Observer 1 using the automatic seed finder on the Variseed
software program. Seed localization was determined on the post-implant MR images
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using information from the pre-implant US volume study images and the knowledge o f
the distribution o f the seeds within the prostate according to the peripheral loading
method. Seed localization on the post-implant MR images were determined for patients 2
through 8. The seeds could not be successfully identified in patient one’s post-implant
MR images due to artifacts and patient motion. Patients 3, 4, and 7 were randomly
selected by Observer 3 for seed localization on the post-implant MR images and for
subjectivity comparisons.
3.2.7 Image Fusion
Two sets o f image fusions were performed during this research. The pre-implant
US images were fused with the pre-implant MR images and the pre-implant US images
were also fused with the post-implant CT and post-implant MR images. To obtain the
most accurate alignment of the two image sets, all o f the images were aligned and fused
with the Variseed software program using the urethra and the bony features in the pelvic
area, with the prostate projected in the transverse, sagittal, and coronal planes. The
images were aligned in the transverse plane by translating and rotating the images from
the two imaging modalities in relation to each other until the prostate, urethra, and bony
features were in agreement. Once the features were aligned in the transverse plane, the
same process was performed in the sagittal and coronal planes. An example o f a 2D slice
o f a fused image is illustrated in Fig. 9.
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I m a g o # 33
P o s l l m n -1.
149 3 a cm

Figure 9. Illustration o f fused axial US and CT images showing the prostate (red) with
isodose lines, urethra (green), and rectum (blue).

3.2.8 Statistical Analysis
The difference, percent difference, mean, and standard deviation were calculated
for prostate volumes delineated from the pre-implant US images, pre and post-implant
MR images, and post-implant CT images.
The Paired Student’s t-test was used to determine if there was a significant
difference between the calculated mean volumes produced from each imaging modality.
The Student’s t-test was calculated for (1) pre-implant US and pre-implant MR, (2) post-
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implant CT and post-implant MR, (3) pre-implant MR contoured by Observer 2 and pre
implant MR contoured by Observer 3, (4) post-implant CT contoured by Observer 1 and
post-implant CT contoured by Observer 3, and (5) post-implant MR contoured by
Observer 2 and post-implant MR contoured by Observer 3. An example o f the
calculations o f the paired Student’s t-test for pre-implant US and pre-implant MR is
given in Appendix I.

3.3 Results
3.3.1 Patient Information
Table 3 lists the age, number o f needles, number o f seeds, activity per seed, total
activity, dose, and planning target volume (PTV) for the eight patients in this study. The
PTVs were determined by the physician during pre-implant planning and includes a 5
mm margin added to the gross tumor. Each patient’s cancer stage fell into the T la to T ic
range with Gleason scores o f 6 and PSA scores ranging from 2.0 ng/ml to 10.0 ng/ml.
The majority o f the prostate cancer was located at the right apex or right mid-base with
two patients having the cancer located at the left mid-gland and left base.
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Table 3. Patient demographics and treatment details for all eight patients in the study.
ID #

Age

Needles

Seeds

1
2
3
4
5
6
7
8

65
71
61
59
62
60
74
66

34
30
31
32
38
40
34
30

112
94
no
116
100
114
107
103

Activity per
Seed (mCi)
0.338
0.383
0.353
0338
0.325
0.354
0333
0.357

Total Activity
(mCi)
35.806
33.153
36.687
37.158
30368
40.394
3332
34.599

Dose

(Gy)

PTV
(cm^)

145
145
145
145
145
145
145
145

58 69
50.92
57.72
5838
49.06
66.37
53.55
54.83

3.3.2 Pre-implant US and Pre-implant MR
The pre-implant US mean prostate volume was 37.9 cm^ with a standard
deviation o f 4.5 cm^. The pre-implant MR mean volume was 41.5 with a standard
deviation o f 7.7 cm^. In comparing these mean prostate volumes, the pre-implant MR
volumes mean is 3.6 cm^ or 9.5% larger than the pre-implant US volumes mean. Since
prostate volumes contoured from MR images are considered to be the gold standard in
brachytherapy, the prostate volumes means from pre-implant US images underestimate
the correct volume mean by 9.5%. Table 4 lists the contoured volumes from the pre
implant US, pre-implant MR, post-implant CT, and post-implant MR images.
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Table 4. Individual and mean prostate volumes with standard deviation contoured from
the pre-implant US, pre-implant MR post-implant CT, and post-implant MR images for
Patient
ID #

Pre-implant
US Volume
(cm^)

Pre-implant
MR Volume
(cm^)

Post-implant
CT Volume
(cm^)

Post-implant
MR Volume
(cm^)

1
2
3
4
5
6
7
8
Mean

3&4
333
353
41.7
32.7
45.8
34.4
40.5
37.9 ± 4.5

43.9
283
42.4
51.0
363
48.5
35.7
46.1
41.5 ± 7 .7

51.9
31.0
3T8
42.3
363
37.0
46.4
53.3
41.5 ± 8 .4

50.5
36.7
48.9
57.3
40.1
56.9
35 3
46.2
46.5 ± 8.4

However, the results from the Student’s t-test calculated for the mean pre-implant
US and pre-implant MR prostate volumes was 2.25 (p= 0.058), showing that there is not
a statistical difference between the two means at the 95% confidence interval for seven
degrees o f freedom.
Though the means between the pre-implant US and pre-implant MR are not
statistically different, there is a large difference among the individual prostate volumes
delineated from the US and MR images. Patient seven had a difference o f only 1.3 cm^
between contoured volumes. Yet patient four had a difference o f 9.3 cm^ in contoured
volumes.
The mean and individual D90 and V I00 dosimetry values for pre-implant US are
listed in Table 5. The mean D90 and VlOO values are 166.9 Gy with a standard deviation
o f 9.3 Gy and 99.4% with a standard deviation o f 0.79%, respectively.
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The fused image o f the pre-implant US and pre-implant MR images shown in Fig.
10 illustrates the difference in size, shape, and positioning o f the contoured prostate
volumes from the two imaging modalities. The prostate volume delineated in the pre
implant MR image extends further out from the contoured volume o f the pre-implant US
image, resulting in a larger volume. It is also less uniform in shape and positioned more
anterior and to the patient’s left in relation to the prostate delineated in the pre-implant
US. The urethra is shown in green with a virtual seed as a green dot with red and green
concentric circles.

Table 5. Individual and mean D90 and VlOO dosimetry values for pre-implant US, postimplant CT, and post-implant MR images for the eight patients._______________________
Patient
1

Pre-implant US
D90 (Gy)
VlOO (%)

Post-implant CT
D90 (Gy)
VlOO (%)

165.1
158.9

100.0
99.6

128.1

3
4

177.2

Post-implant MR
D90 (Gy)
VlOO (%)
NA

NA

152.4

833
91.5

136.2

883

100.0

133.8

8 63

164.4

160.4

99.0

137.0

121.5

5

155.8

97.7

114.2

8633
75.2

9 33
79.9

138/2

883

6

162.6

100.0

78.4

163.4

94.2

7

180.7

99/2

120.9
99 6

75.6

186/2

983

8

174.4

993

106.5

147.0

906

Mean

166.9+9.3

99.4+0.79

124.0±17..3

78.1
81.9±5.9

151.0+21.8

90.3+5.8

2
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Pre-impiant MR

Pre-implant US

Figure 10. Fused image o f pre-implant US (dark red line) with isodose line (light blue
line) and pre-plant MR (red line) illustrating the difference in size, shape, and positioning
o f the prostate volumes delineated in the two imaging modalities. The urethra is
illustrated in green with a virtual seed in green with concentric green and red circles.

3.3.3 Pre-implant US, Post-implant CT, and Post-implant MR
The mean post-implant CT prostate volume was 41.5 cm^ with a standard
deviation o f 8.4 cm^. The mean prostate volume contoured from the post-implant MR
images was 46.5 cm^ with a standard deviation o f 8.4 cm^. Table 4 lists the individual
mean prostate volumes delineated from the post-implant CT and post-implant MR images
for all the patients in the study.
The mean prostate volume contoured from the post-implant CT images were
similar in size to the mean pre-implant US prostate volume o f 37.9 cm^ and identical to
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the mean prostate volume contoured from the pre-implant MR images o f 41.5 cm^. The
least difference in individual prostate volumes between the pre-implant US and post
implant CT o f 0.4 cm^ was seen in patient four with the largest difference o f 13.5 cm^
from patient one. However, the mean prostate volume contoured from the post-implant
MR images was larger than the mean from either the pre-implant US or post-implant CT
images. But a similar difference in the individual prostate volumes between the pre
implant US and post-implant MR is seen with 1.4 cm^ from patient seven and 15.6 cm^
from patient four.
In comparing the results o f the mean prostate volumes among these three imaging
modalities, the mean pre-implant US volume was 9.5% or 3.6 cm^ smaller than the post
implant CT volumes and 22.7% or 8.6 cm^ smaller than the post-implant MR volumes.
The data also shows a difference between post-implant CT and post-implant MR o f
12.0% or 5.0 cm^ with the CT volumes smaller than the post-implant MR volumes.
However, the result o f the Student’s t-test for post-implant CT and post-implant MR is
1.30 (p= 0.235) indicating that there is no statistical difference between their means.
Though the post-implant CT and post-implant MR means are not statistically different,
the individual volumes varied greatly. The prostate volumes contoured from the CT and
MR images o f patient one varied by only 1.4 cm^. However, the prostate volumes
contoured from the CT and MR images o f patient six varied by 19.9 cm^.
The fused image o f the pre-implant US, post-implant CT, and post-implant MR
images shown in Fig. 11 illustrate the volume differences between the US image and the
CT image. Figure 11 also shows how the CT contouring excludes seeds from the
delineated prostate while the MR image matches the shape and contours o f the US image.
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This indicates that MR images are more accurate in representing the actual dimensions of
the prostate than CT images.

Pre-implant US
Fost-impiant CT

Post-implant MR

Figure 11. Fused pre-implant US (yellow), post-implant CT (red), and post-implant MR
(burgundy) images illustrating the difference in prostate volumes between the three
different imaging modalities.

Though there was not a significant difference in the pre-implant US and postimplant CT prostate volumes, there is a difference between their dosimetric values. The
results o f the mean D90 values for pre-implant US, post-implant CT, and post-implant
MR listed in Table 5 show a difference o f 34.6% between pre-implant US and postimplant CT values. However, there was only a difference o f 10.5% between the pre
implant US D90 and the post-implant MR D90 values even though the largest difference
in prostate volumes was between these two imaging modalities. The mean D90 o f 151.0
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Gy with a standard deviation o f 21.8 Gy for MR imaging is also above the cut point o f
140 Gy but the D90 for CT is only 124.0 Gy with a standard deviation o f 17.3 Gy.
Similar resNts are seen with the VlOO values. The CT mean VlOO value is 81.9% with a
standard deviation o f 5.9% which is below the VlOO cut point o f 85% while the MR
mean VlOO value is 90.3% with a standard deviation o f 5.8%.
In identifying the number o f D90 dosimetric values for the CT and MR imaging
modalities that were above an established cut point o f 140 Gy, the results show postimplant CT imaging generating only one out o f eight D90 values above the cut point
while post-implant MR imaging had four out o f seven. Additionally, at a cut point o f
85% for VlOO, post-implant CT imaging had only three out o f eight VlOO values that
were above the cut point while post-implant MR imaging had six out o f seven. With the
correlation o f freedom from biochemical failure to D90 values greater than 140Gy and
VlOO values greater than 85%, these results indicate that MR imaging offers more
accurate dosimetry analysis than CT imaging.
The difference in the individual D90 values between the pre-implant US and postimplant CT ranged from 6.5 Gy for patient two to 81.1 Gy for patient seven. The
difference in the individual VlOO values ranged from 8.1% also for patient two to 22.2%
for patient five. However, a smaller difference was seen in the individual D90 values
between the pre-implant US and post-implant MR with values ranging from 0.9 Gy for
patient six to 27.4 Gy for patient eight. The individual VlOO values that range from 1.2%
for patient seven to 19.1% for patient four. There was also a larger difference in the
individual D90 and VlOO values between post-implant CT and post-implant MR imaging.
The least difference between these two imaging modalities in the D90 values was seen in
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patient four with 15.5 Gy with the largest difference o f 83.6 Gy for patient seven. The
least difference was seen in patient two with 3.3% and the largest difference was 22.4%
for patient seven.
3.3.4 Pre-implant MR, Post-implant CT, and Post-implant MR
Though pre-implant US images are currently being used for pre-treatment
planning, pre-implant MR images could offer better prostate definition resulting in more
accurate dose coverage. In comparing the difference between the mean prostate volume
Ifom the pre-implant MR to the mean prostate volume from the post-implant CT, the two
imaging modalities had the same mean o f 41.5 cm^. But the difference between the pre
implant US and post-implant CT was 9.5%. The ability to easily contour prostate
volumes in MR images is illustrated in the comparison between the mean pre-implant
MR volume of 41.5 cm^ and the mean post-implant MR volumes o f 46.5 cm^. The
difference between the volumes contoured from the pre-implant MR and post-implant
MR images was only 6.0 cm^ or 12.0% compared to a difference o f 8.6 cm^ or 22.7%
between the pre-implant US and post-implant MR.

3.4 Subjectivity
3.4.1 Pre-implant Prostate Volumes
To determine the extent subjectivity affects prostate volume delineation, different
observers contoured the images o f the prostate from different imaging modalities. Results
illustrate very little difference in the mean value among different observers for MR
imaging as shown in Table 6. The mean pre-implant MR prostate volume contoured by
Observer 2 was 41.5 cm^ with a standard deviation o f 7.6 cm^ compared to a mean pre-
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implant MR prostate volume contoured by Observer 3 o f 40.3 cm^ with a 5.8 cm^
standard deviation. This resulted in a 3.0% difference between the mean prostate volumes
with the volumes contoured by Observer 2 being larger. A Student’s t-test for the mean
pre-implant MR volumes showed that there wasn’t a statistical difference between their
means with a t-value o f 1.16 (p= 0.283). Little difference was seen among the individual
prostate volumes contoured by Observer 2 and Observer 3 from the pre-implant MR
images. Patient three had the least difference o f only 0.4 cm^ and patient two had the
largest difference o f 5.1 cm^.

Table 6. Individual and mean pre-implant MR prostate volumes with standard deviation
contoured by Observer 2 and Observer 3.
Pre-implant MR
Pre-implant MR
(Observer 3)
(Observer 2)
Patient
Volume (cm^)
Volume (cm^)
ID #
1
43.9
3&5
2
2R2
3T3
42.4
3
428
51.0
4
4fr9
5
3&2
6
47.4
4&5
7
35.7
3T3
46.1
43.4
8
41.5
±
7
.6
Mean
40.3 ± 5.8

3.4.2 Post-implant Prostate Volumes
The effect o f subjectivity was more evident in the contouring o f prostate volumes
in the post-implant CT images as shown in Table 7. The mean post-implant CT prostate
volume contoured by Observer 1 was 41.5 cm^ with a standard deviation o f 8.4 cm^ and
the mean post-implant CT prostate volume contoured by Observer 3 being 61.3 cm^ with
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a standard deviation o f 9.6 cm^.

This shows a difference in means between the

contouring o f the two CT images o f 47.7% with larger volumes resulting from Observer
3. However, the mean post-implant MR prostate volume contoured by Observer 2 o f 46.6
cm^ with a standard deviation o f 8.4 cm^ was very similar in size to the mean post
implant MR prostate volume contoured by Observer 3 o f 48.7 cm^ with a standard
deviation o f 7.1 cm^. This shows a difference o f 4.7% with the larger volumes resulting
from Observer 3. The individual and mean prostate volumes for the two post-implant MR
images are also given in Table 7.

Table 7. Individual and mean post-implant prostate volumes with standard deviation
calculated from CT and MR images by different observers for the eight patients in the
study.
CT Volume
Observer 1
(cm^)

CT Volume
Observer 3
(cm^)

MR Volume
Observer 2
(cm^)

MR Volume
Observer 3
(cm^)

1
2
3
4
5
6
7

51.9
31.0

65^
52.4
58.1

50.5

50.1
37.4
50.3
58.1
41.7
56.4

8
Mean

523
41.5 ± 8 .4

Patient
ID #

3T8
42 3
36.0
37.0
46.4

74.8
50.7
725
52.0
63^
61.3 ± 9 .6

3fr7
429
57.3
40.1
56 9
328
422
46.6 ± 8.4

44.7
50.6
48.7 ±7.1

The difference in the individual prostate volumes contoured from two post
implant CT images varied the most with a difference o f 5.6 cm^ for patient seven to 36.5
cm^ for patient six. Smaller individual differences were seen between the prostate
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volumes contoured from the two post-implant MR images with a difference o f 0.4 cm^
for patient one and a difference o f 8.9 cm^ for patient six.
O f the four mean post-implant prostate volumes, the prostate volumes contoured
by Observer 3 from the CT images was the largest with 61.3 cm^ with 48.7 cm^
contoured by Observer 3 from the MR images followed by 46.5 cm^ contoured by
Observer 2 from the MR images. The smallest mean o f 41.5 cm^ was contoured from the
CT images by Observer 1. These results illustrate MR imaging as having the least
variability among different observers compared to CT imaging, providing consistent
volume definition among different observers.
A large difference among different observers in delineating prostate volumes in
CT images is illustrated in the results o f the paired Student’s t-test. The result for the
mean CT volumes contoured by Observer 1 and Observer 3 was 5.15 (p= 0.001)
indicating a significant statistical difference at the 99% confidence interval using seven
degrees o f freedom. However, the paired Student’s t-test for the mean MR volumes
contoured by Observer 2 and Observer 3 was 1.90 (p= 0.099). This indicates no statistical
difference between the two means from the different MR images.
The mean D90 and V I00 values calculated from CT images by Observer 1 and
Observer 3 are given in Table 8. This shows very similar results with a difference o f
7.5% between the mean D90 values and a difference o f 3.9% between the mean V I00
values. The two post-implant CT mean D90 values were below the cut point o f 140 Gy
with dosimetry values o f 124.0 Gy with a standard deviation o f 17.3 Gy and 133.3 Gy
with a standard deviation o f 9.0 Gy. The mean V I00 value for post-implant CT contoured
by Observer 1 was also below the 85% cut point with 81.8% with a standard deviation o f
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5.9%. The only mean dosimetry value above the cut point was the mean V I00 value from
the post-implant CT contoured by Observer 3 o f 85.8% with a standard deviation o f
3.3%.

There was also a large difference between the individual D90 values from the CT
images ranging from 0.41 Gy for patient four to 24.4 Gy for patient five. A similar
difference was also seen between the V I00 values with a 0.2% difference from patient
four to 12.7% difference from patient five.

Table 8. The individual and mean D90 and V I00 values for post-implant CT images
contoured by Observer 1 and Observer 3 for all eight patients in the study._____________
Post-implant CT
Post-implant CT
(Observer 1)
(Observer 3)
Patient ID#
D90 (Gy)
V I 0 0 (% )
D90 (Gy)
V I 00 (%)
1

128.1

83/7

125.1

79J

2

152.4

91.5

132.9

828

3

133.8

8 23

1422

8 92

4

137.0

820

137.1

86.2

5

114.2

722

1326

829

6

120.9

724

143.9

89.4

7

99.6

75.6

119.4

83.1

8

106.5

721

126.1

843

Mean

124.0+17.3

81.8±5.9

133.3+9.0

85.8+3.3

The number o f patients who had D90 values above the cut point o f 140 Gy for the
post-implant CT contoured by Observer 1 was one out o f eight with the post-implant CT
contoured by Observer 3 having only two out o f eight. The number o f V 100 values from
the volumes contoured by Observer 1 above 85% was three out eight. The number of
V I00 values from the volumes contoured by Observer 3 above 85% was five out o f eight.
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A comparison o f the D90 and V I00 calculated from volumes obtained from MR
images contoured by Observer 1 and Observer 3 from three randomly selected patients
shows smaller differences than those seen from CT images. The mean D90 and V I00
values calculated from contours produced by Observer 2 and Observer 3 from post
implant MR images are listed in Table 9. Comparing the mean MR D90 value contoured
by Observer 2 o f 157.4 Gy with a standard deviation o f 32.9 Gy and the mean MR D90
value contoured by Observer 3 o f 153.9 Gy with a standard deviation o f 18.8 Gy, there
was only a difference o f 2.3%. And a difference o f only 1.4% was calculated between the
mean MR V I00 value contoured by Observer 2 o f 90.4% with a standard deviation o f
9.4% and the mean MR V I00 value contoured by Observer 2 o f 91.7% with a standard
deviation o f 4.5%. Not only were there smaller differences between the post-implant MR
D90 and V I00 means compared to the post-implant CT D90 and V I00 values, but all the
mean D90 and V I00 dosimetry values for both post-implant MR images were above their
respective cut points o f 140 Gy and 85%.

Table 9. Individual and mean dosimetric values, D90 and V I00, o f the post-implant MR
images calculated from contours produced by Observer 2 and Observer 3 for three
Post-implant MR
(Observer 2)

Post-implant MR
(Observer 3)

Patient ID#

D90 (Gy)

V I 0 0 (% )

D90 (Gy)

V I 0 0 (% )

3
4

164.4

9 33

175.5

927

121.6

79 9

883

7

186/2

98 0

141.5
144.8

Mean

157.4+32.9

90.4+9.4

153.9+18.8

91.7±4.5
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In addition, there were more individual D90 and V I00 values for both post
implant MR images that were above their respective cut points than the individual D09
and V I00 values for both post-implant CT images. The post-implant MR contoured by
Observer 2 had four out o f seven D90 values above 140 Gy and six out o f seven V100
values above 85% as shown in Table 5. Similar results were seen with the post-implant
MR contoured by Observer 3 with three out o f three D90 and three out o f three V I00
values that were above their respective cut points as shown in Table 9.
Though the mean D90 and V I00 values were similar, there was a large difference
seen in the individual D90 and V I00 values between the two post-implant MR images.
The least D90 difference o f 11.1 Gy was seen in patient three with the largest difference
o f 41.4 Gy from patient seven. Similarly, the least V I00 difference o f 3.4% was also seen
from patient three with the greatest difference o f 8.4% from patient four.
Compared to the two post-implant CT mean and individual D90 and V I00 values,
the two post-implant MR had mean dosimetry values and more dosimetry values above
their respective cut points. This suggests MR imaging is capable o f providing more
consistent volume information resulting in better dosimetry information compared to CT
imaging.

3.5 Dose-volume Histograms (DVH)
Dove-volume histograms (DVH) are a crucial analytical tool for providing
qualitative information o f dose distribution and dose coverage to the prostate. DVH were
generated from the pre-implant US, post-implant CT, and post-implant MR images for
patients one through six for comparison to the dose coverage for the PTV. The ability to
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accurately delineate the prostate volumes from the different imaging modalities will
produce greater dose coverage to the volumes.
The DVH were used to determine the amount o f prostate volume that received the
prescribed dose o f 145 Gy from delineation o f the prostate volumes from the pre-implant
US, post-implant CT, and post-implant MR images. The dose coverage to the prostate is
determined by locating the prescribed dose o f 145 Gy on the independent axis and
measuring the volume associated with this value on the individual lines o f the DVH.
From the six patients in the research that had DVH generated from prostate
volume information, five patients’ DVH showed the dose coverage from the post-implant
MR images were superior over the dose coverage from the pre-implant US or post
implant CT images. The DVH in Fig. 12 is from patient three. From this DVH at the 145
Gy prescribed dose, the prostate volume from the post-implant MR images (blue line)
had a dose coverage o f 38.5 cm^ compared to 33.8 cm^ from the pre-implant US images
(light blue line) or 29.1 cm^ from the post-implant CT images (red line). Compared to the
PTV prostate volume o f 52.3 cm^ (burgundy line) for this patient, the post-implant MR
imaging offered better dose coverage due to better prostate volume delineation. O f the
DVH generated for patients one through six, five DVH showed the prostate volumes
contoured from the post-implant MR images provided better dose coverage information.
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Dose Volume Histogram (PTV > MR > US > CT)
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Figure 12. DVH from patient three showing the dose coverage from the post-implant MR
imaging (blue line) had better dose coverage at the prescribed dose o f 145 Gy than from
pre-implant US (light blue line) or post-implant CT (red line) imaging and came closer to
the PTV dose coverage (burgundy line).This type o f DVH was seen in patients two
through six.

Table 10 gives the individual and mean prostate volumes receiving 145 Gy for the
post-implant CT, post-implant MR, pre-implant US, and PTV for patients two through
six illustrating excellent dose coverage from post-implant MR imaging. The mean dose
coverage to the prostates from the post-implant MR imaging for the five patients was
39.1 cm^ with a standard deviation o f 8.6 cm^, 34.0 cm^ with a standard deviation o f 4.4
cm^ for the post-implant US imaging, and 30.1 cm^ with a standard deviation o f 3.6 cm^
for the pre-implant CT imaging. Compared to the mean PTV dose coverage o f 48.5 cm^
with a standard deviation o f 6.6 cm^, post-implant MR imaging provided better dose
coverage to the prostates than the pre-implant US or post-implant CT imaging.
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Table 10. The individual and mean prostate volumes covered at the prescribed dose o f
145 Gy for the post-implant CT, post-implant MR, pre-implant US, and PTV for five out
o f six patients.
Patient
ID#

2
3
4
5
6
Mean

Post-implant CT
Volume (cm^)

Post-implant
MR
Volume (cm^)

Pre-implant
US
Volume (cm^)

PTV
Volume (cm^)

2&3
29.1
36.4
27.4
29J
30.1+3.6

32.7
3&5
49.5
290
45.9
39.1+8.6

326
328
328
27.5
37.4
34.0+4.4

48.0
5 23
53.7
3 25
51.7
48.5+6.6

The only DVH that showed the prostate volume delineated from the post-implant
CT imaging as providing better dose coverage than post-implant MR or pre-implant US
imaging was generated from patient one. The DVH for patient one is shown in Fig. 13. In
this DVH, the dose coverage from the post-implant CT imaging o f 43.5 cm^ was closer to
the dose coverage from the PTV o f 51.6 cm^. This DVH also shows the prostate volume
from the post-implant CT images received more dose coverage at the prescribed dose of
145 Gy than from the volumes delineated from the pre-implant US images o f 35.5 cm^ or
from the post-implant MR images o f 39.1 cm^.
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Dose Volume Histogram (PTV > CT > MR > US)
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Figure 13. DVH from patient one showing the dose coverage from the post-implant CT
(red line) came closer to the PTV dose coverage (burgundy line) than from the pre
implant US (light blue line) or post-implant MR (blue line). This was the only type of
DVH among the six patients.

Comparing the prostate volumes contoured from the pre-implant US, post-implant
CT, and post-implant MR images shown in Table 4, the volumes contoured from the MR
images were larger than the US or CT images for patients two through six. However, for
patient one, the prostate volume contoured from the post-implant CT images was larger
than the volumes contoured from the US or MR images. This result is illustrated in the
superior dose coverage to the prostate from MR imaging in Fig 12.
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3.6 Conclusion
The results o f this research determined that there was a significant difference from
the prostate volumes delineated from the pre and post-implant MR images to prostate
volumes contoured from the pre-implant US or post-implant CT images.
There was a 9.5% or 3.6 cm^ difference between the prostate volumes contoured
from the pre-implant US images to the volumes contoured from the pre-implant MR
images. The difference in the individual prostate volumes between the pre-implant US
and pre-implant MR ranged from 1.3 cm^ to 9.3 cm^. The fused image o f the prostate
from the pre-implant US and pre-implant MR images show the prostate delineated in the
MR image extending more anterior and to the patient’s left in relation to the prostate
delineated in the pre-implant US images. This illustrates that almost 10% o f the prostate
volume is not accounted for in the pre-treatment planning stage o f brachytherapy.
In comparing the means o f the prostate volumes contoured from the pre-implant
US to the volumes contoured from the post-implant CT images, there was also a
difference o f 3.6 cm^ or 9.5%, suggesting that, on average, the images contoured from
CT images produced similar volume estimates. However, the D90 dosimetry values for
the CT imaging were suboptimal with a difference o f 34.6% between pre-implant US and
post-implant CT values. In addition, the post-implant CT imaging had only one out of
eight D90 value above the cut point o f 140 Gy and three out o f eight VIGO values above
the cut point o f 85%. Even the mean D90 o f 124.0 Gy and the mean V I00 values o f
81.9% from the post-implant CT images were below their respective cut points. These
differences are due to seeds being located outside the volume contoured on the CT
images suggest poor contouring due to poor prostate definition.
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The prostate volumes contoured from the post-implant MR images were
significantly larger than the volumes from pre-implant US images probably due to
edema. Compared to the mean pre-implant US prostate volumes, the mean prostate
volume from the post-implant MR images was 22.7% or 8.6 cm^ larger. However, there
was a difference o f only 10.5% between the pre-implant US and the post-implant MR
D90 values. The post-implant MR images also provided more individual D90 and V I00
values above their respective cut points with four out o f seven D90 values above 140 Gy
and six out o f seven V I00 values above 85%. Even the mean D90 value o f 151.0 Gy and
the mean V I00 value o f 90.3% for the post-implant MR were above their respective cut
points.
Though the mean prostate volumes differed, the difference in the individual
prostate volumes between the pre-implant US, post-implant CT, and post-implant MR
was similar. The least difference in the individual prostate volumes was 0.6 Gy between
the US and CT with 1.4 Gy between CT and MR and between US and MR. The largest
difference in the individual prostate volumes was between the CT and MR o f 19.9 Gy
followed by 15.6 Gy between US and MR and 13.5 Gy between US and CT. However,
the same can not be said for the difference between the individual D90 and V I00 values
for the post-implant CT and post-implant MR with the least difference in the D90 values
o f 15.5 Gy with the largest difference o f 83.6 Gy. The same was seen in the VlOO values
with the least difference o f 3.3% and the largest difference o f 22.4%. A large difference
was also seen in the individual D90 and VlOO values between the pre-implant US and
post-implant CT with D90 values ranging from 6.5 Gy to 81.1 Gy and VlOO value
ranging from 8.1% to 22.2%. The smallest difference in the individual D90 and VlOO
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values between the pre-implant US and post-implant MR images with the D90 values
ranging from 0.9 Gy to 27.4 Gy and the VlOO values ranging from 1.2 to 19.1%.
The ability to distinguish prostate volumes in MR imaging provides more
accurate volume definition than CT imaging resulting in better dose coverage as
illustrated in the DVH. In five o f the six DVH generated from the research, prostate
volumes contoured from MR imaging resulted in superior dose coverage to the prostate
compared to volumes contoured from CT imaging. The mean prostate volume receiving
the prescribed dose o f 145 Gy for the post-implant MR imaging was 39.1 cm^ compared
to 33.8 cm^ from the pre-implant US images and 30.1 cm^ from the post-implant CT
images. This supports results from previous research that determined DVH from MR
imaging are more accurate than from CT images (Badiozammani et al. 1999).
Results from this research also show that replacing pre-implant US imaging with
pre-implant MR imaging would create better volume definition for pre-treatment
planning and fusion with either post-implant CT imaging or post-implant MR imaging for
post-implant dosimetry analysis. The mean pre-implant MR prostate volume was the
same as the mean volume from the post-implant CT images compared to a 9.5%
difference between the mean volume from pre-implant US and the mean volume from the
post-implant CT volumes. Similar results were seen with the pre-implant MR and post
implant MR, with a difference o f only 12.0% compared to 22.7% between the prostate
volumes contoured from the pre-implant US and post-implant MR images.
MR imaging also provided better results than CT imaging for delineation o f
prostate volumes among different observers. There was only a 3.0% difference between
the pre-implant MR prostate volumes contoured by Observer 2 and Observer 3 with a
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difference o f 4.7% between the post-implant MR prostate volumes that were contoured
by Observer 2 and Observer 3.

But a difference o f 47.7% was seen in the prostate

volumes contoured from the post-implant CT images by Observer 1 and Observer 3.
When identifying the number o f individual D90 and VlOO values that were above their
respective cut points o f 140 Gy and 85%, the two post-implant MR images were clearly
superior with a total o f seven out o f ten D90 values and a total o f nine out o f ten VlOO
values. However, the two post-implant CT images had only a total o f three out o f sixteen
D90 values and eight out o f sixteen VlOO values that were above their respective cut
points.
There was even a significant difference in the individual prostate volumes, D90,
and VlOO values between the two CT images and the two MR images. The individual
prostate volumes from the two MR images had the least difference with the smallest
difference o f 0.4 cm^ and the largest difference o f 8.9 cm^ compared to 5.6 cm^ and 36.5
cm^ from the two CT images. However, the same can not be said o f the difference in the
D90 values. The smallest difference in the D90 values between the two CT images was
0.41 Gy with the largest difference o f 24.4 Gy. But the smallest difference in the D90
values between two MR images was 11.1 Gy with the largest difference being 41.4 Gy.
The difference in the VlOO values were less pronounced with the smallest difference
between the two CT images o f with a 0.2% and the largest difference o f 12.7%.compared
to o f 3.4% and 8.4% for the two MR images.
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CHAPTER 4

CONCLUSION
4.1

Delineation o f Defined Volumes in CT and MR Images

The results from this research showed a larger discrepancy in the contoured
volumes from the CT images o f the 25 ml, 50 ml, and 100 ml flasks compared to the
contoured volumes from the MR images. The contoured images o f the flasks from the
MR images generated volumes that were smaller than the actual volume o f the flasks, but
to a lesser degree than the volumes contoured from the CT images. Though there was a
significant difference in the magnitude in which the CT images decreased the volumes o f
the flasks compared to the MR images, there was one very distinct similarity between the
two imaging modalities which is crucial in prostate brachytherapy post-implant dosimetry
analysis. The data illustrated that the contoured volume of the 25 ml flask from the CT
and the MR images had a greater degree o f difference compared the contoured volumes
o f the 50 ml and 100 ml flasks, suggesting that post-implant dosimetry analysis would be
less accurate for smaller prostate volumes.

4.2

Comparison o f US, CT, and MR Imaging for Post-implant Dosimetry Analysis
The results from this portion o f the research showed that, though prostate volumes

delineated from pre and post-implant MR images differed in comparison to prostate
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volumes delineated from pre-implant US and post-implant CT images, MR imaging
generated more D90 and VlOO dosimetry values above their respective cut points.
The prostate volumes delineated from the pre-implant MR images differed by
9.5% compared to the volumes contoured in the pre-implant US and post-implant CT
images. But between the mean post-implant MR prostate volume and the mean pre
implant US prostate volume there was 22.7% difference. Though prostate volumes
contoured from CT images were closer to the volumes contoured from US images, the
true shortcoming o f CT imaging for brachytherapy was seen in the dosimetry values. The
majority o f the dosimetry values, D90 and VlOO, from the post-implant CT images were
suboptimal. Compared to the dosimetry values from the post-implant CT images, the
post-implant MR images produced 44.6% more D90 values and 48.2% more VlOO values
above their respective cut points even though the prostate volumes contoured from the
MR images differed the greatest compared to the volumes contoured from the US images.
Even the mean D90 and VlOO values from the post-implant MR images were above the
cut points, but neither mean D90 nor VlOO values from the post-implant CT images were
above the cut points. These results were illustrated in Figure 11 which showed how the
prostate contoured from the post-implant CT image was closer in shape and size to the
volume contoured from the pre-implant US image, but the CT contouring excluded seeds
from the delineated prostate resulting in extremely poor dosimetry information. It also
showed how the prostate contoured from the post-implant MR image extended beyond
the contouring from the pre-implant US, encompassing more implanted seeds and
producing better dosimetry information.
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The criticality o f obtaining accurate prostate volume definition relates to the
implementation o f pre-implant US imaging for pre-treatment planning, implantation
information, and post-implant dosimetry analysis. The results from this research suggest
that replacing pre-implant US imaging with pre-implant MR imaging would generate
better prostate volume definition and dosimetry information. The prostate volumes
delineated from the pre-implant MR and the post-implant CT images had the same mean
volume o f 41.5 cm^ but there was a 9.5% difference between the prostate volumes
delineated from the pre-implant US and post-implant CT images. In addition, there was a
12% difference between the mean prostate volumes contoured from the pre-implant MR
and post-implant MR images but between the mean prostate volumes contoured from the
pre-implant US and the post-implant MR images there was a 22.7% difference. Since the
prostate boundary is well defined in MR images resulting in a more accurate
representation o f the true prostate volume, the 12% difference can be related to edema
resolution. Research has shown that, on average, edema will typically resolve by 88%
after 28 days. Since all eight o f the patients in the study had the post-implant MR scans
performed approximately 30 days after the implant, the 12% difference between the pre
implant and post-implant MR images can be attributed to edema. The benefit o f MR
imaging for dosimetry analysis was also illustrated in the DVH generated from six o f the
patients in the study. Five o f the six DVH showed dose coverage from the post-implant
MR imaging was superior over post-implant CT and pre-implant US imaging. From the
six DVH generated, there was only one DVH which illustrated where the dose coverage
from post-implant CT imaging was superior to dose coverage from the post-implant MR
imaging.
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Subjectivity is a major concern in all prostate brachytherapy post-implant
dosimetry analysis where dosimetry parameters, D90 and VlOO are calculated based on
delineating prostate volumes from CT images. The results from this research showed
prostate delineation from MR imaging is less affected by subjectivity than CT imaging.
The difference between the mean prostate volumes from the pre-implant MR images that
were contoured by Observer 2 and Observer 3 was only or 3.0% with little difference
between the individual prostate volumes. Similar results were obtained with the post
implant MR images with a difference o f 4.7% between the prostate volumes contoured by
Observer 2 and Observer 3. However, a difference o f 47.7% was seen between the mean
post-implant CT prostate volumes contoured by Observer

1 and Observer 3.

Consequently, the difference in individual prostate volumes contoured from the two post
implant CT images were larger compared to the difference in individual prostate volumes
contoured from the two post-implant MR images. In addition, the post-implant MR
images produced better dosimetry values than the post-implant CT images. The post
implant MR images had a total o f seven out o f ten D90 values above 140 Gy and nine out
o f ten VlOO values above 85%. But the post-implant CT images had a total o f three out of
sixteen D90 values and eight out o f sixteen VlOO values. The post-implant CT contoured
by Observer 3 had only one additional D90 value above 140 Gy and two more VlOO
values above 85% than the post-implant CT contoured by Observer 1 even though the
prostate volumes contoured by Observer 1 was 47.7% larger. However, there was a larger
difference in the individual D90 values between the two post-implant MR images than
between the two post-implant CT images. The difference in volumes and dosimetry
values between the two CT images illustrates that the prostate volumes contoured in CT
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images produced dosimetry values below their respective cut points. This suggests that
subjectivity associated with delineating prostate volumes from CT images makes the
accuracy o f the dosimetric evaluation based on CT imaging questionable, concluding that
MR imaging is more precise and accurate in delineating prostate volumes for post
implant dosimetry analysis.

4.3

Overall Conclusion

The results from this research concluded that MR imaging provides more mean
and individual D90 and VlOO values above their respective cut points than CT imaging
due to the ability to adequately delineate the boundary o f the prostate from surrounding
soft tissue in MR images. The data also indicate that MR imaging is less affected by
subjectivity that CT imaging. Though the prostate volumes delineated from the CT
images were closer to the volumes from the pre-implant US images, the individual D90
and VlOO values were suboptimal, indicating that post-implant dosimetry analysis based
on CT imaging gives incorrect dosimetry information in regards to the quality o f the
implant and to the patient’s rate from freedom from biochemical failure. The results o f
this research supports MR imaging for prostate brachytherapy 1-125 pre-treatment
planning, implantation information, and post-implant dosimetry analysis by either
replacing pre-implant US for volume information, replacing CT imaging for seed
localization, or by fusing MR images with CT images to provide correct volume
definition.
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4.4

Recommendations

The results from this research suggest the implementation o f MR imaging for pre
treatment planning and post-implant dosimetry analysis. Implementing MR imaging for
pre-treatment planning can provide a more accurate prostate volume definition resulting
in optimum seed placement within the prostate. For post-implant dosimetry analysis, the
fusion o f MR imaging to provide volume information with CT imaging to provide seed
localization information, would generate more accurate dosimetry information resulting
in a more accurate evaluation in freedom from biochemical failure. Also, the
development o f new MR T2-sequences could provide better seed visualize in addition to
the excellent prostate definition in MR images thereby eliminating the need for post
implant CT imaging.
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APPENDIX I

STUDENT’S T-TEST FOR PRE-IMPLANT US AND PRE-IMPLANT MR
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Table 11. Student’s t-test Calculation for Pre-implant US and Pre-implant MR
Pre-implant US
(cm^)

Pre-implant
MR (cm^)

Difference

Patient
1

3&4

-5.5

2

327
35.9

432)
222
42.4

41.7

51.0

32.7
45.8
34.4
40.5

3&2
425
35.7
46.1

-9 J
-3.5
-2.7
-1.3
-5.6

3
4
5
6
7
8

Zz

(z)

5.5
-6.5

=29.1

n

= 8.0

z

=29.1/8
= 3.6

Ij?

=2424

(Zz)^ / n
= (29Tf/8
= 105.9
Zd^

= Zz^ - ( Z z f / n
= 2 4 2 .4 - 105.9
= 136.5

Od^

= Zd^ / n - 1

= 136.5/8-1
= 19.5
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&d

= V(Od
= 4.4

On

= (Jd/Vn

= 4.4 / a/8
=

t

1.6

= ^ / ffn
= 3.6 / 1.6
= 2.25
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APPENDIX II

HUMAN SUBJECTS RESEARCH PROTOCOL

66

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Human Subjects Research Protocol
Project title:

Post-implant Dosimetry Analysis o f Iodine-125 Brachytherapy Patients by
Delineation o f Prostate Volumes Using Pre- and Post-implant MR!
Imaging

Principal Investigator/Title/Section/Branch/Institute:
Dr. Curtis Mack, MD Arizona Oncology, Tucson, Arizona
Deana Tuttle, Graduate Student, Department o f Health Physics,
University o f Nevada, Las Vegas, NV
Associate Investigators [include name, institution, and city]:
(1) Michael Taylor, Medical Physicist, Arizona Oncology, Tucson,
Arizona
(2) Mark Yoshino, MD, Southern Arizona Diagnostic Imaging, Tucson,
Arizona
(3) Phillip Patton, Ph.D. UNLV, Las Vegas, Nevada

Study type (check all that apply):
X
Archived biological specimens/medical information
________ Natural history; definition o f phenotype, genotype/phenotype correlation
________ Prospective linkage/gene identification, NOT providing information to
participants
________ Prospective linkage/gene identification, providing information provided to
participants
________ Social science; assessments o f knowledge, attitudes and behavior
________ Genetic counseling
________ Drugs or devices
________ Gene transfer
Other interventions
Key Words:
Disease(s)
Prostate Cancer_________________________________________________
Population
Males-diagnosed with prostate cancer undergoing Iodine 125 seed implant
Results routinely communicated to subjects?
X
No
Yes
Research participants to he seen at:
X
Arizona Oncology and Southern Arizona Diagnostic Imaging
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1.

Precis: (In 400 words or few er, describe the study objectives, population, design,
and outcome measures)

(1) Determination o f accuracy and reproducibility o f two different imaging modalities.
This will be accomplished by comparing pre-implant Transrectal Ultrasound (TRUS)
images with pre-implant MR images. TRUS images are used by most physicians as
the standard measurement o f prostate volumes for pre-planning dosimetry. The MR
images will be compared to the TRUS images to determine volume differences.
(2)Determination o f prostate volumes by comparing post-implant CT images with post
implant
MR images. These scans will be performed to determine the extent of post implant
prostate volume differences between the two imaging modalities.
(3) Calculating differences in dose prescribed by the physician in the pre-planning stage
to the total dose in post-implant stage based upon prostate volume differences
determined in pre and post-implant imaging. Using the difference in prostate volumes
between pre-implant TRUS and MR images and between CT and MR post-implant
images, the dose will be calculated and compared to TRUS pre-implant dose
prescribed by the physician to determine the extent of under or over dosage o f the
prostate and surrounding tissue.
Population:
The research will image approximately 10 brachytherapy patients for pre-implant and
post-implant prostate volume evaluation using the MRI at Southern Arizona
Diagnostic Imaging Center . The TRUS pre-implant and CT post-implant imaging
will be performed at Arizona Oncology.
Design and Outcome:
The images obtained from TRUS, MRI, and CT will be contoured to determine
differences in prostate volumes. Then, based upon these differences, the total dose the
prostate received will be calculated and compared to the prescribed dose to identify if
under or over-dosage o f the prostate has occurred on one modality contrasted with the
other.

2.

Objective and specific aims:
The accuracy o f prostate post-implant dosimetry in identifying freedom o f
biochemical failure is dependent upon imaging. I propose to compare our pre-implant
TRUS and post-implant CT images with MR pre and post-implant images to access
the quantitative and qualitative differences. From these results, physicians will be
able to enhance brachytherapy procedures with the goal o f better delineating dose
requirements required for a successful implant. The results o f this study may help
determine systematic and variable differences, perhaps altering the standard o f care in
post-implant dosimetry.
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3.

Brief Rationale and Background;
Post-implant dosimetry analysis is crucial in brachytherapy for determining the dose
the prostate and surrounding tissue received from the permanent seed implants. It
also provides the physician a means o f evaluating seed distribution in relation to
prostate volumes for future prostate cancer patients. However, current studies
indicate a lack o f standard procedures or guidelines for physicians for post-implant
dosimetry analysis in clinical settings (Nag et al. 2000).
Currently, during the preplanning stage o f Brach therapy a Transrectal Ultrasound
(TRUS) is used to determine the clinical target volume (CTV). TRUS images are
also used during surgery for correct seed localization and distribution and prostate
delineation. For post-implant dosimetry, the imaging modality most frequently used
is computed tomography (CT) since seeds cannot be well localized on ultrasound.
TRUS imaging has frequency disruption and artifacts due to the metallic seed
capsules. Though CT is one o f the most common imaging modalities, distinguishing
the prostate base and apex regions from surrounding tissue is difficult. (McLaughlin
et al. 2002; Rasch et al. 1999; Potters et al 2001; Anderson et al. 1999; Graves et al.
2001; Roach, et al. 1996). As a result o f post-implant swelling and poor soft tissue
resolution o f CT images, prostate volumes are on the average 1.4 times larger than
the volumes determined initially in ultrasound and MR images (McLaughlin et al.
2002; Parker et al. 2003; Roach et al. 1996). Therefore, if CT imaging is used as the
sole means o f evaluation in post-implant dosimetry, dose coverage o f the prostate
would be calculated to be less than what was actually prescribed in the preplanning
stage due to the perceived increase in prostate volume. To overcome the limitations
o f CT imaging in defining prostate volume, MR imaging is proposed in pre and post
implant dosimetry.
The significance o f post-implant analysis is for physicians to accurately quantify the
dose delivered and then subsequently relating it to freedom o f biochemical failure.
Current researeh ean support evidence to directly correlate the freedom from
biochemical failure in permanent seed implants to two post-implant parameters,
D90, the dose delivered to 90% o f the prostate volume, and V I00, the amount of
prostate volume receiving 100% o f the prescribed dose (Gong et al. 2002; Stock et
al. 1998; Wallner et al. 2003. This research may assist in altering the standard o f
care in post-implant dosimetry analysis by (I) comparing prostate volumes in pre
implant TRUS images with pre-implant MR images (2) comparing prostate volumes
in post-implant CT images with post-implant MR images and (3) calculating the
differenee in dose prescribed by the physician in pre-planning stage to the total dose
in post-implant stage based upon prostate volumes determined in pre and post
implant imaging.

4.

Description of Study Population:
4.1

Estimated number o f participants, enrollment ceiling, and anticipated
enrollment by year.
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TRUS and MR images will be performed on 3-10 Brachytherapy patients.
Only 3 p re-im p lan t patients will h av e the MRI scan if a p attern appears
indicating prostate volumes for pre-implant TRUS and MR images are
consistent with a difference o f approximately 1.07. The TRUS images will be
obtained at Arizona Oncology office and the MR images will be obtained at
Southern Arizona Diagnostic Imaging office. The MRI data will be
transferred to Dicom where the prostate volumes will be contoured on
Variseed software. Prostate volumes will be determined during the standard
volume study by the physician.

The standard post-implant CT will be performed in addition to MRI scans for
10 brachytherapy patients. These scans will be performed to determine the
extend o f post implant prostate volume differences between the two imaging
modalities. The CT images will be done at Arizona Oncology Office and the
M R images will be obtained at Southern Arizona Diagnostic Imaging office.

4.2

Description o f clinical inclusion/exclusion criteria.
Eligible participants will be limited to males diagnosed with prostate cancer
scheduled to undergo a prostate seed implant and who are not prescribed
hormone therapy to reduce prostate size nor are they receiving external beam
treatment.

4.3

Location o f study.
The study will be performed at Arizona Oncology office located at West
Orange Grove, Building 1, Tucson, Arizona and at Southern Arizona
Diagnostic Imaging, 1845 West Orange Grove, Suite 103, Tucson, Arizona.

4.4

Description o f recruitment strategies
Recruitment will be done by Dr. Curtis Mack, MD at Arizona Oncology
Office.

4.5

For existing sample/data sets, note whether samples were originally collected
for research or clinical practice. If obtained for research, include a description
o f the original purpose o f study and prior plans for sample storage. Was
consent obtained that would be applicable to this study? (Include copy o f
original consent forms!)
This research study is based upon identifying differences in imaging
modalities in delineation o f the prostate o f cancer patients in determining total
dose to the organ and surrounding tissues for identifying freedom from
biochemical failure. A consent form is included in the packet o f forms for
submittal to the IRB committee.
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4.6

Description and justification o f inclusion/exclusion o f participants.
The objectives previously stated specifies that the participants be male, and
within the standard age o f men seen previously with prostate cancer. Patients
undergoing hormonal treatment are excluded because the prostate volume
changes under this additional source.

4.7

Description o f efforts to include under-represented minorities.
Not-applicable.

4.8

Description o f any financial compensation. If participant withdraws early,
describe how compensation will be modified.
Since this research is based upon pre and post implant MR imaging performed
during standard treatment form prostate cancer, the participant will not be
financially compensated.

Description of procedures: (Please include a flo w s h e e t or chart).
5.1

Approved Drugs
Not-applicable.

5.2

Unapproved Drugs/Device^'
Not-applicable.

5.3

Diagnostic studies
Not-applicable.

5.4

Biological Specimens
Not-applicable.

5.5

Medical information
Not-applicable.

5.6

Describe questionnaires or other psychological instruments and estimate how
long they will take to complete, and whether they address sensitive topics
Not-applicable.

5.7

Specific results that will be given to participants or their health care providers
Not-applicable.
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5.8

Genetic counseling
Not-applicable.

5.9

Description o f criteria for withdrawal from study.
(1) Determination o f prostate volumes by comparing pre-implant TRUS
images with pre-implant MR images.
TRUS and MR images will be performed on 3-10 Brachytherapy patients.
The TRUS images will be obtained at Arizona Oncology office and the MR
images will be obtained at Southern Arizona Diagnostic Imaging office.
The MRI data will be transferred to Dicom where the prostate volumes will be
contoured on Variseed software. Prostate volumes will be determined during
the standard
volume study by the physician.
(2) Brachytherapy Iiodine-125 Seed Implant Surgery.
Dr. Curtis Mack, MD will perform the Iodine-125 permanent seed implant at
Northwest Medical Center. Approximate time will be 1.0 to 1.5 hours. The
preplanning stage o f brachytherapy uses Transrectal Ultrasound (TRUS) in
the volume study to determine the clinical target volume (CTV). TRUS
images are also used during surgery for correct seed localization and
distribution and prostate delineation.
(3) Post-implant examination in determination o f prostate volumes by
comparing
post implant
CT images with post-implant MR images
approximately 30 days after surgery.
The standard post-implant CT will be performed in addition to MRI scans for
10 brachytherapy patients. The CT images will be done at the Arizona
Oncology office and the MR images will be obtained at Southern Arizona
Diagnostic Imaging office. The rectal coil in post-implant MR images is not
recommended due to the need to keep consistent parameters with post-implant
CT images that do not require rectal coils.
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Figure 14. Flow-chart o f brachytherapy implantation procedures.
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6.

D escrip tion o f statistical con sid eration s an d /or analytic plan

In pre-implant data analysis, the prostate volumes will be compared from the
standard Transreetal Ultrasound (TRUS) images, contoured during the
Volume Study by Dr. Curtis Mack, MD, to volumes determined in the MR
images. A previous study has indicated that TRUS prostate images were
comparable in size to MRI prostate images, with a differenee o f only 1.07.
Only 3 pre-implant patients will have the MRI scan if a pattern appears
indicating prostate volumes for pre-implant TRUS and MRI images are
consistent with a differenee o f approximately 1.07.
During the post-implant data analysis, prostate volumes will be compared
from the standard CT images to MR images. Both MRI and the CT images are
contoured using a Variseed Software program. Since soft tissue is difficult to
distinguish on CT images, contouring the prostate to determine volume for
dosimetry is very subjective. Post-implant swelling and poor resolution o f soft
tissue results in a prostate volume larger that the TRUS volume generally used
in pretreatment planning. In previous studies, CT prostate volumes were on
the average, 1.4 times larger than the volumes determined initially in
ultrasound or MR imaging studies.
Post-implant Brachytherapy dosimetry analysis will use the data from the pre
and post implant prostate volumes to determine the dosage to the prostate and
surrounding tissue.
7.

Description of potential benefits of study
7.1

Direct benefits to participants (physical or psychosocial)
The MRI scans are not physically or psychosocially beneficial to the patient.
The
scans are performed as a means o f identifying a prostate
volume differences and are only an addition to the standard brachytherapy
procedures.

7.2

Collateral benefit to participants (medical or genetic counseling care)
The MRI scans are not beneficial to the diagnosis or treatment o f the patient.
The scans are being performed in conjunction with the standard Brach therapy
Transreetal Ultrasound (TRUS) and Computer Topography (CT) scans..
However, additional biological and anatomical patient information obtained
by another imaging modality increases the possibility o f identifying any
abnormalities. In the event an investigator notices an abnormality on an MRI
scan, a physician will be consulted as to whether the finding merits further
investigation, in which ease the investigator will contact you and your primary
care physician and inform you o f the finding.
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7.3

Benefits to society
The accuracy o f prostate post-implant dosimetry in identifying freedom o f
biochemical failure is dependent upon imaging. This research proposes to
compare standard pre-implant TRUS and post-implant CT images with MRI
pre and post-implant images to access the quantitative and qualitative
differences. The images obtained from TRUS, MRI, and CT will be contoured
to determine differences in prostate volumes. Then, based upon these
differences, the total dose the prostate received will be calculated and
compared to the prescribed dose to identify if under or over-dosage o f the
prostate has occurred. From these results, physicians will be able to modify
brachytherapy procedures with the goal o f improving dose distributions
perhaps increasing the life expectancy o f the patients based upon improved
D90 and V I00 values, perhaps decreasing side effects by limiting doses.

8.

Description of likelihood and seriousness of harms and how safety will be
maximized
MRI Scans:
The MRI machine uses a strong magnet and radiowaves to make images o f
the body’s interior. The scanning procedure is very much like an x-ray CT
scan. You will be asked to lie on a long narrow couch for a certain amount o f
time (approximately 30 minutes) while the machine gathers data.
During this time you will not be exposed to x-rays, but rather a magnetic
field and radiofrequency magnetic fields. You will not feel either. You will,
however, hear repetitive tapping noises that arise from the MR scanner. We
will provide earplugs or ear phones that you will be required to wear. The
space within the large magnet in which you lie is somewhat confined,
although we have taken many steps to relieve the "claustrophobic" feeling.
Risks:
Magnetic fields do not cause harmful effects at the levels used in the MRI
machine. However, the MR scanner uses a very strong magnet that will
attract some metals and affect some electronic devices. If you have a cardiac
pacemaker or any other biomedical device in or on your body, it is very
important that you tell the operator/investigator immediately. As metallic
objects may experience a strong attraction to the magnet, it is also very
important that you notify the operator o f any metal objects (especially
surgical clips), devices, or implants that are in or on your body before
entering the magnet room. All such objects must be removed (if possible)
before entering the magnet room. In some cases, having those devices means
you should not have an MRI scan performed. In addition, watches and credit
cards should also be removed as these could be damaged. You will be
provided a way to secure these items. If you have any history o f head or eye

75

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

injury involving metal fragments, if you have ever worked in a metal shop, or
if you could be pregnant, you should notify the operator/investigator.
Subjects will be screened in the same manner as all patients having routine
MR to exclude those with pacers and/or cerebral aneurysm clips.
If you have had a previous reaction to Gadolinium-based contrast agents or a
history o f severe allergies, please notify the operator/investigator.
Some o f the RF imaging eoils, imaging software and devices being used in
your scan are not approved by the FDA but are similar to counterparts that
have been approved by the FDA. There is a small risk o f heating from the
cables associated with these devices. Please report any heating sensation
immediately.
The scans performed in this study are for specific research purposes and are not
optimized to find medical abnormalities. The investigators for this project may not
he trained to perform medical diagnosis. The investigators and Arizona Oncology
Office and Southern Arizona Diagnostic Imaging offices are not responsible for
failure to find existing abnormalities with these MRI scans. However, on occasion
the investigator may notice a finding on an MRI scan that seems abnormal. When
this occurs, a physician will be consulted as to whether the finding merits further
investigation, in which case the investigator will contact you and your primary
care physician and inform you o f the finding. The decision as to whether to
proceed with further examination or treatment lies solely with you and your
physician. The investigators and the consulting physician, are not responsible for
any examination or treatment that you undertake based on these findings. Because
the images collected in this study may not comprise a proper clinical MRI scan,
these images will not be made available for diagnostic purposes.

8.1

Drugs/deviees/gene transfer
Not-applicable.

8.2

Radiation
Not-applicable.

8.3

Sedation
Not-applicable.

8.4

Psychological harms (misunderstanding, anxiety, selfesteem , depression)
Not-applicable.

76

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

8.5

Risks to family relationships
Not-applieable.

8.6

Discrimination
Not-applicable.

9.

Collection, monitoring, analysis and reporting of adverse events
9.1

If this is either a natural history or limited encounter protocol, explain this to
the IRB and specify the occurrenees that will be excluded from adverse event
reporting.
Not-applicable.

9.2

Describe plan to monitor adverse events as defined in Section 8.0 for this
protocol, {anticipated and unanticipated, serious and non-serious)
Not-applicable.

9.3

Describe plan to report adverse events as defined for this protocol in
accordance with NIH and NHGRl regulations. (Note that all serious adverse
events as defined fo r this pro to co l must be reported in writing by mandated
deadlines to the N H G R l Clinical Director, NHGRI IRB, and other agencies, if
pertinent.)
Not-applicable.

9.4

Describe whether a Data Safety and Monitoring Board (DSMB) will be used.
Not-applieable.

10. Description
of
how
privacy
and
confidentiality
information/biological specimens will be maximized

of

medical

10.1 Will participant identifiers be attached to data, or will samples/data be coded
or unlinked.^ (Even i f names are removed, how likely is potential
identification ?)
10.2 Description o f any clinical/demographic information that will be included.
{age, ethnicity, sex, diagnosis, stage, treatment)
10.3 How might this information make specific individuals or families identifiable?
10.4 If research data will be coded, how will access to the “key” for the code be
limited?
Include description o f security measures {password-protected
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database, locked drawer, other).
access to the key.

List names or positions o f persons with

10.5 Will pedigrees be published? Include description o f measures to minimize the
chance o f identifying specific families.
10.6 Will any results be provided to participants or their health care providers?
Explain.
10.7 Will personally identifiable information be released to third parties?
10.8 Under what circumstances will data/samples be shared with other researchers?
10.9 Describe any additional features to protect confidentiality.
Only team members directly involved with your care and the research will have
access to information, data, and results o f the study. All information and data
from this study will be identified with a code number instead o f your name. The
key for this code will be stored in a locked file cabinet.
The pre and post Iodine-125 implant MR images o f the prostate that we collect
from you may be shared with other researchers in the future, linked together with
other information such as your age, gender, and ethnicity. If this information is
shared, we will not give other researchers your name, address, or phone number.
Your name and all identifying information will be removed. There will be a code
to link your data with your name and other personal information.
If future research on your pre and post Iodine-125 implant MR images o f the
prostate provides important information related to your health, we will try to
contact you. If you wish to be contacted, you must let Dr. Curtis Mack, MD at
Arizona Oncology know about changes in your address or phone number.
11. Description of alternatives to participation
interventions that participants should consider.)

(Other

elinical or

research

Not-applieable.
12. Assessment of significance of study (Reasonableness o f risks to participants in
relation to the anticipated benefits o f the study.)
The reasonable risk to participants is minimal since the pre operative Ultrasound and
post-implant CT scan necessary for this study are part o f the standard treatment
routine for prostate cancer patients. The only addition is the MRI studies to be done
pre and post implant. MR imaging is safe and non-invasive, producing images with
significant boundary definition o f prostate volumes. The benefits o f having the same
patients imaged pre and post-implant, is considerable when identifying volume
differences in relation to total dose the prostate and surrounding tissue received in
post-implant dosimetry analysis. If CT imaging is used as the sole means o f
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evaluation in post-implant dosimetry, dose coverage o f the prostate will not be as
accurate. Though techniques have been developed to improve CT post-implant
dosimetry, we feel there is room for significant improvement.
13. Description of specific funding source and budget. (If p ro ject is funded from P i ’s
discretionary budget, this should ju s t be noted without budget)
13.1

Clinical Center funds (clinical tests, nursing, in-patient days, etc.)

13.2 DIR resources (data management, statistics, non Clinical Center testing, and
contracts.)
Funding for this research comes from the Northwest Medical Center.
14. Description of Consent Process
14.1

Who will obtain consent (PI, study coordinator, and prim ary physician)? If
collaborators who are not designated as eo-investigators will be obtaining
consent, the consent form should be signed by both the PI and the collaborator
who is obtaining consent.

14.2 Setting where consent will be obtained (location o f in-person discussion,
phone, mail).
14.3 What information will be provided to participants? (Include consent form and
any other related material, including information about stored tissues and
pedigrees).
14.4 Protections for participants who may be vulnerable to coercion or undue
influences (pregnant women, fetuses, children, people with impaired decision
making ability).
14.5 Will children be studied? (Include c o w o f assent form).
14.6 Are there special circumstances regarding obtaining consent? (W aived
consent, opt-out, verbal consent, consent with speakers o f other languages
and translation o f materials into other languages.)
Participant’s consent will be obtained by Dr. Curtis Mack, MD, at Arizona
Oncology, 1845 West Orange Grove, Building 1, 520-544-2919 during the
initial volume study.
A Consent Form is included in this packet.
Participants unable to make rational decisions in regards to study participation
will not be included.
(11/29/00)
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